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Summary
Multi ple sclerosis (MS) is the most common infl ammatory disease of the central nervous 
system (CNS) and its animal model experimental autoimmune encephalomyeliti s (EAE) 
is mediated by the acti ons of auto-reacti ve encephalitogenic TH cells. While TH1 cells 
were long considered to be the major pathogenic populati on, the discovery that IL-23 
and not the TH1 inducing cytokine IL-12 is vital for EAE development initi ated a major 
paradigm shift  with regards to the role of TH1 cells in infl ammati on. IL-23 supports the 
expansion of IL-17 secreti ng TH cells, which are now considered to be the pathogenic 
populati on mediati ng autoimmunity as IL-17 expression by T cells correlates closely with 
an autoimmune pathogenic phenotype and this polarizati on patt ern was termed TH17. 
However, IL-17A in contrast to IL-23 does not appear to be an absolute requirement for 
the development of autoimmune disease and other features appear to be inherent to this 
pathogenic TH cell populati on. 
We identi fi ed IL-22 as well as IL-17F to be induced by IL-23 in encephalitogenic CD4+ T 
cells and could show that both cytokines are specifi cally secreted by TH17 cells implicati ng 
them as additi onal encephalitogenic cytokines. To determine the role of these cytokines 
in autoimmune infl ammati on, we generated IL-22-/- and IL-17F-/- mice. In contrast to the 
noti on that genes associated with CNS-invading T cells imply their pathogenic functi on, 
we found IL-22-/- as well as IL-17F-/- mice to be fully suscepti ble to EAE. 
Taken together, we show that self-reacti ve T cells coexpress IL-17A, IL-22 and IL-17F, but 
that neither IL-22 nor IL-17F are involved in autoimmune pathogenesis of EAE. 
On human blood-brain barrier endothelial cells in multi ple sclerosis lesions, we could 
demonstrate the expression of IL-17 and IL-22 receptors and show that IL-17 and IL-22 
disrupt BBB ti ght juncti ons in vitro and in vivo. We could further detect numerous IL-17 
or IL-22 expressing T cells in highly infi ltrated MS lesions and observed that these cells 
produced cytolyti c enzymes such as granzyme B. Granzyme B+ TH17 cells had the capacity 
to kill human fetal neuron–enriched cultures and showed considerable cytolyti c acti vity 
as compared to unacti vated T cells. 
Therefore, we conclude that additi onal factors expressed by TH17 cells or induced by 
IL-23 – disti nct from IL-17A, IL-17F and IL-22 – exist that play a role in autoimmune 
infl ammati on.
Zusammenfassung
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Zusammenfassung
Multi ple Sklerose (MS) ist die am weitesten verbreitete infl ammatorische 
Autoimmunerkrankung des Zentralnervensystems (ZNS) und das entprechende 
Tiermodell experimentelle autoimmune Enzephalomyeliti s (EAE) wird durch autoreakti ve 
enzephalitogene TH Zellen hervorgerufen. Lange wurden die pathogenen Eigenschaft en der 
TH1-Zellpopulati on zugeschrieben, doch die Entdeckung, dass nicht das TH1 induzierende 
Zytokin IL-12, sondern IL-23 für die Entwicklung von EAE verantwortlich ist, führte zu einem 
Paradigmenwechsel bezüglich der Rolle von TH1 Zellen in entzündlichen Erkrankungen. IL-
23 bewirkt die Expansion von IL-17 exprimierenden TH Zellen, die nun als pathogene und 
Autoimmunität vermitt elnde Zellpopulati on angesehen werden, da die IL-17 Expression 
eng mit einem autoimmunen Phänotyp assoziiert ist. Diese IL-17 sekreti erenden T-Zellen 
werden als TH17 Zellen bezeichnet. Im Gegensatz zu IL-23 scheint IL-17A allerdings keine 
absolute Voraussetzung für die Entwicklung von Autoimmunerkrankungen zu sein und 
TH17 Zellen scheinen weitere Moleküle mit proinfl ammatorischen Eigenschaft en zu 
exprimieren. 
Wir konnten zeigen, dass IL-22 und IL-17F durch IL-23 induziert, von enzephalitogenen 
CD4+ T-Zellen exprimiert und als weitere TH17 Zytokine anzusehen sind. Um die Rolle 
dieser Zytokine in Autoimmunentzündungen näher zu untersuchen, haben wir IL-22-/- 
und IL-17F-/- Mäuse hergestellt. Im Gegensatz zur Annahme, dass mit ZNS infi ltrierenden 
T-Zellen assoziierte Gene eine pathogene Funkti on bedeuten, entwickelten IL-22-/- und 
IL-17F-/- Mäuse normale EAE. Zusammenfassend können wir zeigen, dass autoimmune 
T-Zellen IL-17A, IL-17F und IL-22 koexprimieren, allerdings weder IL-22 noch IL-17F in der 
Entwicklung von EAE eine Rolle spielen.
Wir konnten die Rezeptoren für IL-17 und IL-22 auf humanen Endothelzellen der 
Bluthirnschranke in MS Läsionen nachweisen und zeigen, dass IL-17 und IL-22 die 
Zellverbindungen der Bluthirnschranke zerstören – sowohl in vitro als auch in vivo. 
Desweiteren konnten wir eine Vielzahl von IL-17 und IL-22 exprimierenden T-Zellen in 
infi ltrierten MS Läsionen detekti eren und feststellen, dass diese zytolyti sche Enzyme wie 
Granzym B exprimieren. Granzym B+ TH17 Zellen waren in der Lage, neuron-angereicherte 
Zellkulturen zu lysieren und zeigten im Vergleich zu nicht akti vierten T-Zellen eine 
beachtliche zytolyti sche Akti vität.
Insgesamt können wir den Schluss ziehen, dass weitere Faktoren – exprimiert von TH17 
Zellen bzw. induziert durch IL-23 – existi eren, die eine wichti ge Rolle in der Entwicklung 
von Autoimmunentzündungen spielen.
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Introduction
The immune system
The immune system is a complex network of organs and cells that protect the body against 
pathogens or infecti ous agents, such as viruses, bacteria, fungi and other parasites. It can 
be divided into two disti nct but intertwined systems: the innate and the adapti ve immune 
system. Innate immunity is present in all vertebrates as well as in plants and insects and 
allows the recogniti on of pathogens and microbes through preformed receptors (1). 
Adapti ve immunity is a feature of higher vertebrates which allows the recogniti on of 
foreign structures through receptors which are molded in primary lymphoid organs by 
means of somati c recombinati on. Mature lymphocytes, namely T- and B-cells, carry such 
recombined receptors. Adapti ve immunity furthermore has developed a vital feature of 
immunity - the capacity to “remember” formerly encountered anti gens. While innate 
immunity originally was considered a primiti ve predecessor of adapti ve immunity, it has 
become clear that the development of adapti ve immune responses absolutely requires 
the assistance of innate immunity and to some extend vice versa (2).
Innate immunity
The innate immune response provides a fi rst line of defense for the organism in 
controlling infecti ons in the fi rst days before an initi al adapti ve immune response takes 
place. The components of the innate immune system are natural killer (NK) cells, γ/δ 
T cells, polymorphonuclear cells (PMNs) and professional anti gen presenti ng cells 
(APCs) like monocytes/macrophages and dendriti c cells (DCs). Its functi on is based on 
the recogniti on of pathogen-associated molecular patt erns (PAMPs), which are typically 
nucleic acids or conserved components of cell wall structures from microorganisms. 
PAMPs are recognized by germ-line encoded receptors known as patt ern recogniti on 
receptors (PRR) (3),which include membrane-bound receptors on the cell surface like 
Nucleoti de-binding oligomerizati on domain proteins (NOD) recognizing components of 
pepti doglycan and mediate intracellular recogniti on of bacteria (4) as well as soluble 
proteins secreted into the blood like mannose-binding lecti ns (MBL) (5), C-reacti ve protein 
(CRP) (6) or complement (7). The most important type of membrane-bound PRRs are the 
toll-like receptors (TLRs), which are expressed on DCs and macrophages (1). Nowadays, 
11 diﬀ erent TLRs have been characterized in mice (8). Among them bacterial CpG DNA 
is recognized by TLR9, cell wall components of Gram-positi ve bacteria by TLR2 and TLR4 
functi ons as the patt ern of recogniti on receptor for LPS. Engagement of TLRs promotes 
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the engulfment and destructi on of microorganisms and leads to increased phagocyti c 
acti vity, release of proinfl ammatory factors and secreti on of chemokines and cytokines. 
Most importantly, APC acti vati on and maturati on is a requirement to acti vate and drive 
adapti ve immunity (2).
Adaptive immunity
The adapti ve immune system recognizes foreign structures through highly specifi c 
receptors which are generated by somati c recombinati on and therefore oﬀ ers a more 
precise and eﬃ  cient recogniti on of pathogens as compared to innate immunity. Most 
importantly, adapti ve immunity generates immunological memory, which enables rapid 
immune acti vati on upon reinfecti on. The adapti ve immune response includes B-cell 
mediated humoral immunity and T cell mediated cellular immunity. 
B-cells mature in the bone marrow and express a unique B-cell receptor (BCR), which is a 
membrane bound anti body molecule. Anti bodies are made up of a variable region which 
Figure 1: Schemati c illustrati on of the inducti on and eﬀ ects of TH1, TH2 and TH17 cells.
The cytokines secreted by anti gen presenti ng cells during T cell acti vati on direct the diﬀ erenti ati on 
of naïve CD4+ T cells towards one of diﬀ erent eﬀ ector TH cell lineages which secrete characteristi c 
cytokines and exert disti nct functi ons.The classical TH1 polarizing factors include type I and II IFNs, 
IL-12, IL-18 and IFN-γ produced by TH1 cells is important in the regulati on of anti gen presentati on 
and cellular immunity, while the TH2-cell cytokines regulate B-cell responses and are crucial me-
diators of allergic diseases. TH17 cells, which are triggered by TGF-β, IL-6 and IL-23 express IL-17, 
IL-17F, IL-21 and IL-22 and mediate infl ammatory responses. IL: interleukin, IFN: interferon, TNF: 
tumor necrosis factor, TGF-β: transforming growth factor-β.
Introduction
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includes the highly specifi c anti gen (Ag)-binding site and a constant region, which defi nes 
the diﬀ erent classes of anti bodies. In mice and humans the diﬀ erent isotypes of anti bodies 
are IgM, IgG, IgA, IgD and IgE, which diﬀ er in structure, eﬀ ector functi on, localizati on 
and serum concentrati on. Anti bodies protect the host by neutralizati on through binding 
to structures on the surface of pathogens, by opsonizati on which is achieved by coati ng 
the pathogen and promotes phagocytosis and subsequent eliminati on of the pathogen 
or by acti vati on of the complement system. The complement system strongly enhances 
opsonizati on, but can also lead to direct killing of certain bacterial cells by inserti ng pores 
in their membranes. The type of eﬀ ector mechanism depends in part on the anti body 
isotype. Isotype switching occurs aft er B-cell acti vati on and leads to producti on of diﬀ erent 
classes of anti bodies. B-cell acti vati on can be T cell dependent or T cell independent. Most 
anti gens are T cell dependent, in which case Ag crosslinking the BCR provides the fi rst 
signal necessary for B-cell acti vati on and the second signal comes from co-sti mulati on 
provided by a T helper (TH) cell, which produces cytokines that trigger B-cell proliferati on 
and diﬀ erenti ati on into an anti body secreti ng plasma cell. Isotype switching and memory 
cell generati on occur in response to T cell dependent anti gens. T cell independent anti gens 
oft en comprise structural epitopes like repeati ng carbohydrate epitopes that can sti mulate 
B-cells without TH cell help (9).
T cells are also generated in the bone marrow but migrate to the thymus for maturati on 
during which they undergo a positi ve selecti on for the recogniti on of self major 
histocompati bility complex (MHC) molecules, followed by a negati ve selecti on. During 
negati ve selecti on, T cells expressing a T cell receptor (TCR) recognizing self-pepti des are 
eliminated to prevent an immune response against the bodies own ti ssues. T cells that 
survived positi ve as well as negati ve selecti on in the thymus circle in a naïve stage through 
the body via the blood and lymph streams. T lymphocytes only recognize processed 
pepti de anti gens presented on MHC molecules (10) - cytotoxic CD8+ T cells react to pepti de 
bound on MHC class I molecules which are expressed by virtually all cells of the body 
and CD4+ TH cells recognize MHC class II bound pepti de. MHC class II molecules are only 
expressed by professional APCs and contact between an APC providing a suitable MHC/
pepti de complex (signal 1) and an additi onal costi mulatory signal (signal 2) is required for 
the acti vati on of the T cell, a process called priming. Therefore, APCs can be seen as the 
link between innate and adapti ve immunity. Two of the best characterized costi mulatory 
molecules expressed by APCs are CD80 (B7.1) and CD86 (B7.2) which interact with CD28 
or CTLA-4 expressed on T cells, providing a sti mulatory or inhibitory signal, respecti vely. 
CTLA-4 is only expressed upon acti vati on of T cells and therefore serves to contain the 
immune response. Acti vati on of T cells without co-sti mulati on may lead to T cell anergy 
or deleti on. T cells also provide sti mulatory signals for APCs through expression of CD40L 
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which interacts with its receptor CD40 on APCs (11). CD40 signaling leads to cell acti vati on 
and survival and further upregulati on of costi mulatory molecules.
The cytokines secreted by APCs are referred to as a third signal during T cell acti vati on and 
greatly infl uence the outcome of the immune response as TH cells can diﬀ erenti ate into 
one of several subtypes with disti nct functi ons depending on the cytokine environment 
(Fig. 1).
The classical TH1 polarizing factors include type I and II interferons (IFNs), interleukin (IL-) 
12, IL-18 and TH1 cells secrete IFN-γ and IL-2 (12) leading to acti vati on of macrophages 
and CD8+ T cells. In turn, in the absence of TH1 cytokines and through IL-4 polarized TH2 
cells a humoral immune response is supported by secreti on of IL-4 (13) which leads to an 
acti vati on of anti body secreti ng B-cells and the complement system. This classical TH1/
TH2 paradigm has been recently updated aft er additi onal eﬀ ector T cell types have been 
identi fi ed, i.e. IL-17 producing TH17 cells which polarizati on is mediated by TGF-β, IL-6 and 
IL-23 (14,15,65,79,195). Moreover, additi onal CD4+ subsets such as TH3 cells, T regulatory 
type 1 (TR1) cells, TGF-β induced regulatory T cells and follicular helper T (TFH) cells have 
been characterized (16). Regulatory T cells (Treg) are important in maintaining peripheral 
tolerance and limiti ng extensive immune response via direct cell-cell contacts and/or by 
the producti on of suppressive cytokines like IL-10 and TGF-β.
Acti vated CD8+ cytotoxic T lymphocytes (CTLs) are able to destroy their target cells 
through inducti on of apoptosis, either using perforin and granzymes (17) or Fas-ligand 
interacti on (18,19). In the fi rst pathway, cytoplasmic granule toxins — predominantly 
the membrane-disrupti ng protein perforin — and a family of structurally related serine 
proteases (granzymes) with various substrate specifi citi es are secreted by exocytosis and 
together induce apoptosis of the target cell. The existence of CD4+ CTLs, which are able to 
perform perforin and granzyme-mediated killing, has also been reported (20).
Autoimmunity
Autoimmunity is caused by an adapti ve immune response against “self” anti gen. Normally, 
lypmhocytes expressing an anti gen receptor that recognizes self anti gen are eliminated 
during negati ve selecti on. As soon as a developing lymphocyte expresses its anti gen 
receptor on the cell surface, its anti gen-recogniti on properti es are tested. Specifi city and 
aﬃ  nity towards molecules present in the immediate environment, which is the bone 
marrow and fetal liver for B-cells and the thymus for T cells, are tested. 
Strong autoanti gens that crosslink the BCR lead to eliminati on of these autoreacti ve 
B-cells through cell death or apoptosis (21,22). Furthermore, the B-cell can be rescued 
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by rearranging the BCR and creati ng a self-tolerant BCR by receptor-editi ng (23). Weak 
autoanti gens can lead to anergy of the B-cell which then dies relati vely soon due to 
missing survival signals from T cells. Some autoreacti ve B-cells however, which did not 
encounter their anti gen during development as it is not present in the compartments of 
lymphopoisis, might be released into the periphery and lead to autoimmunity.
T cells expressing a TCR that recognizes a self pepti de in the context of a MHC molecule 
are eliminated during negati ve selecti on in the thymus – a mechanism known as central 
tolerance. It is clear however, that thymic selecti on is not a perfect process and that 
autoreacti ve T cells are frequently released into the periphery. One reason for this is that 
not all peripheral self-anti gens are expressed within the thymus and those that are may 
not always be present at suﬃ  cient levels to cause deleti on. To keep these potenti ally 
harmful T cells in check, several control mechanisms exist that are collecti vely referred 
to as peripheral tolerance. Potenti ally harmful cells can either be rendered anergic 
(i.e. functi onally unresponsive), deleted by apoptosis, or suppressed by Treg cells within 
secondary lymphoid or non-lymphoid organs (24-26).
If, however, all control mechanisms fail, the immune system can att ack the body’s own 
ti ssues and initi ate an autoimmune disease. Autoimmune diseases can be systemic and 
directed against various organs or organ-specifi c. The majority of systemic autoimmune 
diseases like systemic lupus erythematusus (SLE) result from humoral immune responses 
and the producti on of autoanti bodies, whereas organ-specifi c autoimmune diseases 
like Insulin-dependent (Type I) diabetes mellitus where pancreati c β-cells are the target, 
rheumatoid arthriti s (RA) in which the joint synovium is att acked or multi ple sclerosis are 
generally believed to be cell mediated.
Multiple Sclerosis
Multi ple sclerosis (MS) is a complex demyelinati ng disease associated with infl ammati on in 
the central nervous system (CNS) and is thought to be driven by an autoimmune process. 
It develops in young adults and common features are paralysis, sensory disturbances, lack 
of coordinati on and visual impairment (27), whereas the clinical manifestati ons of MS 
among aﬀ ected individuals are extremely variable. Pathologically, MS is characterized by 
lesions or plaques found in the CNS white matt er, which result from focal loss of myelin 
and are localized throughout the CNS, but predominantly reside within the periventricular 
regions, opti c nerves, brain stem and spinal cord. The sites of acti ve demyelinati on are 
characterized by infi ltrati on of MHC class II expressing macrophages, B-cells and acti vated 
CD4+ T cells secreti ng disti nct cytokines (28). The acti vati on of autoreacti ve CD4+ T cells 
against components of the myelin sheath and their diﬀ erenti ati on into a pathogenic 
phenotype are considered crucial events in the initi al phase, whereas further damage 
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of the CNS is most likely mediated by other components of the immune system, such as 
anti bodies, complement, CD8+ T cells and factors produced by innate immune cells. At the 
same ti me, a degenerati ve process disti nct from the recurrent infl ammati on is thought to 
be responsible for the progressive loss of neural cells and neurological functi ons (29).
Despite intensive scienti fi c research, the eti ology of MS remains largely unknown, but is 
widely accepted to be an autoimmune disease which suscepti bility is infl uenced by both 
geneti c and exogenous factors.
Experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyeliti s (EAE) serves as an animal model of MS. 
It can be induced in suscepti ble rodents by immunizati on with myelin anti gens such as 
myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) or proteolipid 
protein (PLP) or by adopti vely transferring an expanded populati on of myelin-reacti ve 
encephalitogenic CD4+ T cells (30-32). EAE cannot be transferred by anti bodies and has 
so far only been reported 2 ti mes to be inducible by the transfer of CD8+ cells (33,34), 
emphasizing the important role of CD4+ T cells. 
The sequence of immunopathological events leading to EAE can be divided into an initi al 
T cell priming and acti vati on phase and a subsequent recruitment and eﬀ ector phase (35). 
Aft er immunizati on with myelin anti gens, these are taken up and presented by professional 
APCs in secondary lymphoid organs which results in the acti vati on and expansion of auto-
aggressive, myelin-reacti ve T cells. In the EAE model, adjuvants such as complete Freund’s 
or microbial DNA containing CpG moti ves are generally used to break immune tolerance 
against self-structures and initi ate APC acti vati on and maturati on. Immunizati on with 
soluble Ag does not suﬃ  ce to induce autoimmunity. Aft er successful priming, acti vated 
myelin-reacti ve T cells migrate to the CNS where they reencounter their Ag in the context 
of an APC (36) followed by blood brain barrier (BBB) permeabilizati on allowing them 
to migrate deeper into the CNS parenchyma (37). The producti on of proinfl ammatory 
cytokines such as tumor necrosis factor (TNF) and IFN-γ, leads to the up-regulati on of 
MHC class II molecules on APCs and also of adhesion molecules on the BBB endothelium. 
This will facilitate the further infl ux and acti vati on of cells, thus contributi ng to the 
amplifi cati on of the infl ammatory immune response ulti mately leading to demyelinati on. 
Other than disease inducti on, the steps involved in the pathogenesis of EAE and MS are 
thought to be similar.
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The blood brain barrier
The CNS has long been considered to be an immune privileged organ. The concept of 
immune privilege was drawn upon the observati on, that allograft s showed prolonged 
survival in the CNS while being rapidly rejected by the immune system when graft ed into 
other sites, such as skin (37a).  Due to the lack of draining lyphati cs and the presence of the 
BBB, the CNS was regarded as being immunologically inert and completely isolated from 
the peripheral immune system. However, recent data revealing types of cellular immune 
responses that occur within the CNS proved that it is neither isolated nor passive in its 
interacti on with the immune system. Peripheral immune cells can cross the intact BBB, glia 
and neurons acti vely regulate macrophage and lymphocyte responses and microglial cells 
are immunocompetent. It was suggested, that specifi c types of immune responses are even 
required for the maintenance of normal CNS functi on and the inducti on of regenerati on 
(38-40). Therefore, immune privilege is rather the sum of CNS driven mechanisms acti vely 
regulati ng T cell responses within the CNS than a complete immune isolati on.
In the old view of immune privilege as immune isolati on, the most important element 
protecti ng the CNS from damage mediated by the immune system was the presence of 
an intact BBB – hence, the percepti on of the BBB as a ti ght and impermeable barrier has 
also shift ed (41). 
The BBB is a specialized system of brain microvascular endothelial cells (BMVEC) that are 
in contact with the endfeet of astrocytes and pericytes and forms a diﬀ usion barrier for 
hydrophilic blood molecules (35). It ensures constant supply of nutrients for brain cells and 
controls entry of immune cells into the CNS, which is rare under physiological conditi ons 
as the transport across the BBB is strictly limited through both metabolic (enzymes, 
diverse transport systems) and physical barriers (ti ght juncti ons). The enzymati c barrier 
at the cerebral endothelium can metabolize drugs, nutrients and neuroacti ve bloodborne 
solutes and makes the BBB a working and nonstagnant membrane that maintains brain 
homeostasis. A ti ght juncti on is composed of the integral transmembrane proteins 
occludin, the claudins and the juncti onal adhesion molecules. These ti ght juncti on proteins 
are connected to the acti n cytoskeleton by anchoring proteins such as zonula occludens 
(ZO)-1, ZO-2 and ZO-3. The presence of ti ght juncti ons in the intact BBB has long been 
assumed to prevent leukocyte migrati on from the blood into the CNS (42). However, during 
a variety of pathological conditi ons of the CNS such as viral or bacterial infecti ons, or during 
infl ammatory diseases like MS or EAE, immunocompetent cells easily cross the BBB (43). 
Impairment of the BBB during CNS infl ammati on is thought to result from disrupti on of 
juncti on complexes between BMVEC with subsequent formati on of a paracellular route, 
facilitati ng entry of leukocytes into the brain parenchyma (44). However, the cause/eﬀ ect 
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relati onship between BBB disrupti on and subsequent CNS infi ltrati on of autoreacti ve 
leukocytes is sti ll uncertain – solely breaking the BBB does not automati cally result in 
autoimmunity. The undermined immune privilege in this situati on might have additi onal 
reasons like the appearance of DCs, the establishment of terti ary lymphoid ti ssue in the 
meninges, or local immunosti mulatory eﬀ ects of cytokines and chemokines (45). 
T cells and cytokines in autoimmunity
The TH1-TH2 paradigm
In 1986, Mossman and Coﬀ man proposed the TH1-TH2 hypothesis, which classifi es TH 
cells in diﬀ erent categories depending on their cytokine expression profi le and functi on 
(46). As described above, TH1 cells produce IFN-γ, while TH2 cells secrete IL-4, IL-5, IL-10 
and IL-13. These reciprocally inhibitory cytokine profi les are mediated by lineage-specifi c 
transcripti on mechanisms. IL-4 drives the diﬀ erenti ati on of TH2 cells, mediated by signal 
transducer and acti vator of transcripti on (STAT) 6 dependent upregulati on of GATA-binding 
protein 3 (GATA-3), a transcripti on factor necessary and suﬃ  cient for TH cells to diﬀ erenti ate 
into a TH2 phenotype. The transcripti on factor crucial for TH1 cell development is T-bet, 
which amplifi es the IFN-γ expression and suppresses the producti on of TH2 cytokines. An 
important signaling molecule leading to this is STAT4, which is acti vated following IL-12 
receptor engagement. 
The two T cell subtypes exert disti nct functi ons in adapti ve immunity: TH1 cells mediate 
cellular immunity, while TH2 cells regulate humoral immunity and allergic responses (47).
However, if these eﬀ ector functi ons are uncontrolled and persistent, the onset of 
autoimmunity, allergy or atopy can be driven. Evidence from clinical observati ons and 
from studies on experimental animals supports the idea that uncontrolled TH2 cell 
responses cause the development of atopic diseases, such as asthma (48). On the other 
hand, abnormal TH1 cell responses have been associated with many autoimmune diseases, 
including psoriasis, infl ammatory bowel disease (IBD), MS and EAE (49,50). Due to the 
crucial role of IL-12 in TH1 diﬀ erenti ati on, this cytokine and its role in autoimmunity has 
been extensively investi gated.
Interleukin-12: a central cytokine in immunity
The cytokine IL-12 was fi rst identi fi ed by Kobayashi et al. in 1989 (51) and was shown to 
be a heterodimeric cytokine of 70kDa consisti ng of two disulfi de linked subunits, a heavy 
p40 and a light p35 chain (52-54) (Fig. 2). The genes encoding p35 and p40 are located 
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on diﬀ erent chromosomes and therefore, protein expression is regulated independently 
of each subunit. p35 is expressed ubiquitously and consti tuti vely at low levels (30) and 
requires coexpression of p40 for secreti on of the biologically acti ve cytokine from the 
cell. Expression of p40 is highly inducible by microbial products and limited to APCs like 
monocytes, macrophages, DCs and to a lesser extent B-cells (51,55). 
The IL-12 receptor (IL-12R) complex is, just like its ligand, composed of two subunits – 
β1 and β2 (Fig. 2) and is expressed predominantly on NK cells and on acti vated, but not 
on resti ng T cells (56). DCs were also shown to express IL-12R and because these APCs 
secrete acti ve IL-12 as well, an autocrine eﬀ ect of this cytokine can be concluded (57). 
Coinciding with the dominant role of IL-12 in TH1 polarizati on, the expression of IL-12Rβ2 
on TH1 cells is ti ghtly regulated, as its expression is maintained by IFN-γ which induces the 
transcripti on factor T-bet, whereas IL-4 inhibits the expression of β2. Therefore, expression 
of a complete IL-12R has been suggested as a determinant of the TH1 phenotype (58). A 
variety of diﬀ erent pathogens induce high levels of IL-12p40 and IL-12p70 producti on 
in infected hosts, including gram-positi ve and gram-negati ve bacteria, parasites, viruses 
and fungi. IL-12 producti on is strongly induced in cells of the innate immune system via 
TLR signaling by microbial products (59). T cell dependent acti vati on of IL-12 producti on 
Figure 2: Structure, receptors 
and main signalling pathways 
of IL-12 and IL-23.
The heterodimeric cytokines IL-
12 and IL-23 – both composed 
of two disulfi de linked subunits 
– are produced by anti gen pre-
senti ng cells like DCs and mac-
rophages.  Although they share 
similariti es in structure, they act 
on diﬀ erent cells of the immune 
system. The receptors of IL-12 
and IL-23 are both composed 
of two chains which have to be 
coexpressed in order to gener-
ate functi onal cytokine binding 
sites. Following ligand binding, 
the signal transducti on leads to 
acti vati on of the JAK/STAT path-
way. IL-12 predominantly induc-
es homodimerizati on of STAT4, 
whereas IL-23 mainly induces 
formati on of STAT3/STAT4 het-
erodimers. 
IL: interleukin, STAT: signal trans-
ducers and acti vators of tran-
scripti on, TYK: tyrosin kinase, 
JAK: janus kinase
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through the engagement of CD40 on APCs with its cognate ligand CD40L on T cells was 
also described (60).
The biological eﬀ ects of IL-12 on its primary targets, CD4+ and CD8+ T cells and NK cells, are 
manifold. IL-12 induces the producti on of other cytokines like GM-CSF, TNF, IL-2, but most 
importantly IFN-γ, which coordinate the ensuing immune response. IFN-γ sti mulates the 
bactericidal acti vity of phagocytes and enhances the innate immune response. Moreover, 
it potently induces further IL-12 producti on by monocytes and PMN. Another important 
functi on of the cytokine is the increase of CD8+ T cell and NK cell cytotoxicity which is 
at least partly achieved by an upregulated expression of adhesion molecules as well as 
perforin, granzyme B and other granule-associated proteins (61). 
IL-12 is in fact best known for its ability to regulate adapti ve immunity by directi ng the 
polarizati on of naïve CD4+ lymphocytes towards a TH1 phenotype and is the most criti cal 
cytokine promoti ng TH1 diﬀ erenti ati on and expansion (62,63). TH1 cells produce IFN-γ and 
are crucial for the cell mediated immune response against intracellular pathogens, viruses 
and bacteria. On the other side, IL-12 and IFN-γ antagonize TH2 development and therefore 
limit the producti on of IL-4, IL-5 and IL-13.
IL-12 in autoimmunity
Due to the central functi on of IL-12 in infl ammati on, its properti es have been extensively 
studied in the context of autoimmunity. A number of experimental observati ons led to the 
assumpti on that IL-12 is a key player in MS pathogenesis. Increased levels of IL-12 in serum 
(64), cerebrospinal fl uid (CSF) (65) and MS lesions as well as IL-12 producing peripheral 
blood mononuclear cells (PBMC) in MS pati ents could be detected when compared to 
controls (66). Van Boxel et al. showed that the level of IL-12p40 mRNA was elevated in MS 
pati ents during the development of acti ve lesions and that in relapsing-remitti  ng MS the 
increase occurred immediately prior to relapses (67). Ozenci et al. could show, that there 
is an increased number of IL-12Rβ1 and β2 expressing T cells in the CSF of MS pati ents 
compared to controls (68). Through various studies in EAE, in which IL-12p40-defi cient 
mice were uti lized, recombinant IL-12 administered or the cytokine blocked with anti  IL-
12p40 anti body, IL-12 had been classifi ed as a disease promoti ng cytokine. In acti vely 
induced EAE in Lewis rats, IL-12 mRNA expression in the CNS emerges early during the 
initi al period and culminates at the peak of disease, consistent with a disease promoti ng 
role of this cytokine (69-71). A correlati on between the expression of IL-12p40 mRNA and 
the clinical course of EAE could also be observed in SJL/J mice. Experiments by Segal and 
colleagues demonstrated impressively the importance of IL-12p40 in EAE: They found, 
that injecti on of neutralizing anti bodies against IL-12p40 during the priming of donor 
mice rendered encephalitogenic myelin-reacti ve T cells harmless (72). Furthermore, it was 
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reported that anti -IL-12p40 anti body suppresses EAE in adopti ve transfer recipients (73). 
Using IL-12p40-defi cient mice, it could further be shown that these mice are completely 
resistant to EAE induced by acti ve immunizati on with myelin anti gens (72).
In summary, IL-12 appears to have a crucial and non-redundant capacity to polarize TH1 
immunity and to be absolutely vital for the development of autoimmunity. However, as 
discussed below, it remains to be seen as to whether the properti es associated to IL-12 in 
vivo are indeed specifi c to IL-12 or whether other factors are contributi ng to the phenomena 
described above.
Discordant behaviour of IL-12p40- and p35-deficient mice
The fact that TH1 immunity is considered to be the driving force behind autoimmune 
diseases such as MS and RA implicates the strong role of IL-12 as well as TH1 cytokines 
such as IFN-γ and TNF-α. Surprisingly, mice lacking either IFN-γ or TNF-α were shown to be 
highly suscepti ble to autoimmune diseases like EAE (74-76). However, the dogma that TH1 
immunity is a prerequisite for autoimmunity persisted, mainly due to the data obtained 
from IL-12p40-defi cient mice. As discussed above, IL-12p70 consists of two disti nctly 
regulated subunits, p40 as well as p35. The group of M. Gately has generated mice 
both defi cient in IL-12p35 and p40 (77). Initi al reports suggested that their behaviour in 
response to parasiti c and mycobacterial infecti ons is equally impeded by the loss of either 
subunit (77). In EAE however, Becher et al. observed a discordant clinical development 
in p35- and p40-defi cient mice. Even though IL-12p40-defi cient mice are EAE resistant, 
p35-defi cient mice develop EAE with increased severity compared to wild type (wt) mice 
(78). This fi nding was also confi rmed by others (79). Conversely, mice lacking the IL-12Rβ1 
subunit were EAE resistant, but the β2 subunit was shown to be irrelevant (80). This led to 
the noti on, that p40 may either act as a monomeric cytokine or as a homodimer. Indeed, 
p40 can also form a homodimer p80 that binds to IL-12Rβ1 and therefore antagonizes 
IL-12 signalling (81,82). It might also have a direct agonisti c functi on as a macrophage 
chemoatt ractant in vitro and in vivo, but the responsible receptor has not been identi fi ed 
yet (83-85). However, p40 has also been shown to be a subunit of IL-23 and the biology of 
this newly identi fi ed cytokine will be described in the following.
Interleukin 23: changing the verdict on IL-12 function in inflammation and 
autoimmunity
The recently described cytokine IL-23 is also a member of the IL-6 cytokine-family and has 
similar but discrete functi ons from IL-12 (86). Like IL-12, it is comprised of two disulfi de-
linked subunits designated p40, which is shared by IL-12, and a unique protein termed p19 
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(Fig. 2). The p19 component is produced in large amounts in acti vated macrophages, DCs, 
T cells and endothelial cells where its producti on is directly induced by CD40-crosslinking 
and indirectly by IL-1 and IFN-β (87,88). TH1 cells express more p19 mRNA than do TH2 cells, 
however, among these cell types, only acti vated APCs such as monocytes, macrophages 
and DCs concomitantly express IL-12p40 (89,90). 
The IL-23 receptor consists of the IL-12Rβ1 subunit which is shared with the IL-12 receptor 
and the IL-23R subunit (91) (Fig. 2). IL-23R subunit expression has been demonstrated on 
acti vated/memory T cells, NK cell lines, EBV-transformed B-cells, but also on monocytes, 
macrophages and DCs (91,92). IL-23 sti mulati on leads to acti vati on and phosphorylati on 
of diﬀ erent STATs, joining IL-12 and type I IFNs by also using STAT4 as a transcripti on factor. 
However, in contrast to IL-12, IL-23 preferenti ally acti vates STAT3, with its receptor binding 
to STAT4 being quite weak compared to that of IL-12R (91), a fact that might explain why 
the biological eﬀ ects of these cytokines are similar but not identi cal (Fig. 2). In additi on 
to the presence of IL-23R on accessory cells, the expression of the IL-23R chain was found 
to be much higher on CD4+CD45RBlo memory cells than on CD4+CD45RBhi naïve cells (91). 
The opposite patt ern of expression was observed for IL-12Rβ2. This unique expression 
patt ern of IL-23R is consistent with a stronger functi onal response of memory T cells to 
IL-23 when compared to naïve T cells (86,93-95). 
IL-23 in autoimmunity: making sense of the observed discrepancies
Over the past ten years, it was believed that the ability of IL-12 to strongly promote the 
development of TH1 cells made it an ideal target for the treatment of TH1 cell-mediated 
diseases like autoimmunity. The role of endogenous IL-12 had been addressed by using 
IL-12p40-defi cient mice or by administering anti -IL-12p40 anti bodies. However, although 
the infl ammatory response in these models was characterized by IFN-γ producti on, the 
role of IFN-γ in the development of infl ammati on was less clear. In two diﬀ erent disease 
models of autoimmunity, EAE and CIA, it could be shown that, while p40 was important 
for the development of autoimmune infl ammati on, the absence of IFN-γ resulted in the 
development of a more severe pathology (74,76,96). The discrepancy between the role 
of IL-12p40 and IFN-γ in these models of infl ammati on was inconsistent with a linear 
model in which IL-12 drives a pathological autoimmune TH1-cell response and indicated 
an important role of IL-12 in the development auf autoimmunity. 
But with the controversial observed phenotypes of mice defi cient in IL-12p40 or IL-
12Rβ1 compared to those lacking either IL-12p35 or IL-12Rβ2, it became clear that, while 
p40 is absolutely criti cal for the development of diﬀ erent experimental diseases, IL-12 
is completely dispensable (78-80,97,98). The discovery of IL-23, which shares the p40 
chain and the IL-12Rβ1 with IL-12, has started to provide an explanati on to the numerous 
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observati ons existi ng in the literature and provided indirect evidence that IL-23 has an 
important functi on in controlling certain infecti ons and T cell mediated autoimmune 
responses. 
The fi rst indirect evidence for the importance of a p40-containing cytokine other than 
IL-12 came from studies using p35 gene-targeted mice in EAE. p35-/- mice lack bioacti ve 
IL-12 but have normal levels of IL-23 and oﬀ er a unique tool to diﬀ erenti ate the role 
of IL-12 from IL-23. While EAE could not be induced in IL-12p40-defi cient mice, the 
disease was even more severe in p35- or IL-12Rβ2-defi cient mice than in wt mice (78-80) 
suggesti ng a redundancy of the IL-12 system in the inducti on of EAE. It could be shown 
that in the suscepti ble IL-12p35-defi cient mice the disease was associated either with 
a downregulati on of the autoanti gen-specifi c TH1 response (78) or even a deviati on to 
TH2 (79). This confi rmed the importance of biologically acti ve IL-12 in orchestrati ng TH1 
type immune responses, but illustrated that EAE can develop under TH2 conditi ons. These 
fi ndings together with the resistance of p40-defi cient mice suggested that other p40-
containing cytokines, such as IL-23, are required for establishment of the disease. In 
experiments in which a bone marrow chimeric mouse model was used so that p40 was 
deleted from the CNS parenchyma, but not the systemic immune compartment, it could 
be shown that p40 is not absolutely required for the infi ltrati on of infl ammatory cells into 
the CNS but that p40 produced by cells resident to the CNS is essenti al for the maintenance 
of encephalitogenicity of T cells migrati ng into the CNS (78). This fi nding was confi rmed in 
IL-23p19-defi cient mice, which are, similar to p40 knockout mice, completely resistant to 
EAE inducti on (99). Cua et al. further demonstrated that administrati on of IL-23 into the 
CNS of p19 knockout mice just before disease onset can abrogate the resistance to EAE 
whereas injecti on of IL-12 into IL-12p40-defi cient mice had no eﬀ ect. However, when the 
IL-12 treatment (at an early ti me point in the disease) was followed by administrati on of 
IL-23 into the CNS, EAE comparable with that seen in wt mice was induced. 
A very similar role for IL-12 and IL-23 has been observed in the inducti on of another 
autoimmune disease, CIA. Mice specifi cally lacking IL-23 (p19-defi cient) and those 
animals lacking both IL-12 and IL-23 (p40-defi cient) were resistant to CIA inducti on. 
Neither p40- nor p19-defi cient mice revealed pathology upon histological examinati on of 
joints whereas mice specifi cally lacking only IL-12 (p35-defi cient) were highly suscepti ble 
to CIA. Disease severity appeared to be more intense in p35-defi cient mice compared 
with wt mice as was also seen in EAE experiments. Disease recovery was delayed in mice 
lacking only IL-12. Thus, IL-23, but not IL-12, is necessary for the development of joint 
autoimmune infl ammati on and the absence of IL-12 may result in a more severe disease. 
It is now established that IL-23 drives the development of CD4+ T cells into a new subset 
of  IL-17 producing TH cells which can be linked to autoimmune diseases (14,15). Thus, the 
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development of a disti nct lineage of CD4+ T cells expressing IL-17 now further explains 
the diﬀ erent acti ons of IL-12 and IL-23 in regulati on of ti ssue infl ammatory reacti ons and 
autoimmunity. 
TH17 cells
The fi rst ti me, a unique IL-17A producing TH cell subset diﬀ erent from the classic TH1 
and TH2 paradigm has been suggested was in 2000 (100). Infante-Duarte and colleagues 
observed that naïve T cells primed by a lysate of B. burgdorfei developed a phenotype 
disti nct from T cells primed under TH1 and TH2 conditi ons, with much higher IL-17A 
secreti on. They also proposed that IL-6 might play a role in the development of these IL-
17A-producing TH cells. Gurney and colleges could then show that IL-23 enhances IL-17 
producti on from memory but not naïve CD4+ T cells (97). Together, these observati ons 
led to the hypothesis that IL-23 is required for the development and/or expansion of the 
now – based on the expression of their characteristi c cytokine – TH17 termed new lineage 
of infl ammatory TH cells (14,15,101). The characteristi c cytokine expression profi le of TH17 
cells includes IL-17A and IL-17F, IL-22, IL-21 and TNF-α (102).
The transcripti on factor RORγt, a reti noid orphan nuclear receptor, is specifi cally expressed 
in both human and mouse TH17 cells and necessary and suﬃ  cient to induce IL-17A, IL-17F 
and IL-23R expression (103). RORγt upregulati on is dependent on STAT3, but for maximal 
IL-17 producti on functi onal STAT4 also seems to be required (104,105). Recently, Yang et 
al. reported, that RORα is also expressed by TH17 cells, but compared to RORγt it seems 
to be a minor player in TH17 diﬀ erenti ati on (106).
It is sti ll a matt er of debate, which factors and cytokines are responsible for the initi al 
regulati on of TH17 cell lineage commitment. The fi rst two papers describing the de novo 
inducti on of TH17 cells reported that IL-23 was, in the absence of IFN-γ and IL-4, the criti cal 
TH17 inducing factor (14,15). However, shortly aft erwards it was demonstrated that TGF-β 
and IL-6 were suﬃ  cient for TH17 diﬀ erenti ati on and also induced RORγt upregulati on 
(107-109). These fi ndings together with the IL-23R being absent on naïve T cells argue 
against IL-23 being required for initi al TH17 diﬀ erenti ati on and raise the questi on of the 
role of IL-23 for TH17 cells. The most common hypothesis is that IL-23 is important for 
the expansion of diﬀ erenti ated TH17 cells or maintainance of IL-17 producti on. These 
assumpti ons stem from in vitro observati ons that the presence of IL-23 during culture 
of acti vated cells results in increased proliferati on of acti vated T cells (93) and increased 
frequencies of IL-17 secreti ng cells (101) and that IL-23 was required during resti mulati on 
of TGF-β plus IL-6-sti mulated cells to maintain their IL-17 producti on (109). It has also 
been proposed, that IL-23 might stabilize the TH17 phenotype through STAT3-dependent 
mechanisms (106,110) or that IL-23 is a survival factor for TH17 cells (111).
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The fact that TGF-β is involved in TH17 inducti on was unexpected, since TGF-β is known to 
induce the expression of FoxP3 and the development of Treg cells. Therefore, IL-6 seems to 
infl uence the acti on of TGF-β by inhibiti ng Treg cells on one side (112) and by upregulati ng 
TH17 promoti ng factors such as IL-23R and IL-21 in T cells on the other (103,110). The 
discovery of a crucial regulatory role for reti noic acid in promoti ng FoxP3 inducti on and 
inhibiti ng TH17 cell diﬀ erenti ati on further supports a reciprocal relati onship between 
inducible Treg and TH17 cells (113). IL-21 is secreted by TH17 cells and acts in an autocrine 
manner to further promote TH17 cells. It might, however, not be essenti al for TH17 lineage 
commitment or their pathogenic functi ons. Furthermore, IL-1β was found to promote 
TH17 cell development or proliferati on in the presence of IL-6 and TGF-β (109).
Like TH1 and TH2 cytokines reciprocally inhibit the other cell type, TH17 cells are also 
negati vely regulated by several cytokines. On the one hand by TH1 and TH2 cytokines like 
IL-12, IFN-γ, or IL-4, which additi on to cultures inhibits IL-23- as well as TGF-β plus IL-6-
sti mulated diﬀ erenti ati on of mouse and human TH17 cells (14,15,114) and on the other 
hand, TH17 cells are inhibited by IL-10 and IL-27. IL-10 has been proposed to be a self-
regulatory mechanism as this cytokine is expressed by TH17 aft er conti nued exposure 
of diﬀ erenti ati ng TH17 cells to TGF-β and IL-6 (115). IL-27 was fi rst identi fi ed as a TH1 
inducing, proinfl ammatory cytokine. However, it has recently been demonstrated that it 
exerts immunoregulatory functi ons by suppressing the development and proliferati on of 
TH17 cells, thereby limiti ng autoimmune infl ammati on (116,117).
The factors inducing TH17 diﬀ erenti ati on in humans are less clear but seem to diﬀ er from 
those required in mice to some extent. However, the phenotypes of human and murine 
TH17 cells comprise many similariti es. In both cases, IL-17A, IL-17F and IL-22 are hallmark 
cytokines and the expression of the IL-23R and the chemokine receptor CCR6 additi onally 
defi ne this subset (113).
Most importantly, TH17 cells are now closely associated with a number of murine and 
human autoimmune disorders like CIA, IBD, MS and EAE. The role and functi on of the TH17 
cytokines IL-17A, IL-17F and IL-22 will be described in the following.
IL-17A and IL-17F
IL-17A is the founding member of the IL-17 family of cytokines, which includes fi ve 
other members, named IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25) and IL-17F. IL-
17A was originally cloned and described by Rouvier et al. (118). IL-17F shares the 
greatest homology (55%) with IL-17A and the genes encoding these two cytokines are 
located in close proximity on the same chromosome in mice and humans. IL-17A and 
IL-17F are produced by TH17 cells, whereas IL-17B, IL-17C and IL-17D are produced by 
non T cell sources. IL-17A and IL-17F can either exist as IL-17A homodimers and IL-17F 
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homodimers or as IL-17A-IL-17F heterodimers (119). The IL-17 receptor family consists of 
fi ve, broadly distributed receptors with individual ligand specifi citi es. Within this family 
of receptors, IL-17R (also known as IL-17RA) is the best characterized, it binds IL-17A 
and is expressed in multi ple ti ssues: vascular endothelial cells, peripheral T cells, B-cell 
lineages, fi broblast, lung, myelomonocyti c cells and stromal cells. Recently, IL-17RA was 
shown to also form a heterodimer with IL-17RC, (120) another member of the IL-17R 
family and there is evidence that IL-17RC binds IL-17F (121). IL-17A also binds to IL-17RC, 
but altogether it is sti ll not clear whether IL-17 and IL-17F homodimers, as well as the 
IL-17–IL-17F heterodimer, preferenti ally interact with IL-17RA and IL-17RC homodimers 
or heterodimers. Upon engagement, acti vati on of nuclear factor-κB (NF-κB) and JUN 
amino-terminal kinase (JNK) signaling pathways are induced in a tumor-necrosis factor 
receptor (TNFR)-associated factor 6 (TRAF6)-dependent manner (122). ACT1, another 
adaptor protein has been identi fi ed recently. It serves as an immediate and essenti al 
signaling component of IL-17R (123), associates with the intracellular region of IL-17RA 
and is required for NF-κB acti vati on and the inducti on of many pro-infl ammatory genes 
by IL-17. Both IL-17A and IL-17F mainly act on fi broblasts, epithelial and endothelial cells, 
exert pro-infl ammatory eﬀ ects and induce cytokines (IL-6, GM-CSF, G-CSF), chemokines 
(IL-8, CXCL1, CXCL10) and matrix metalloproteinases (16). IL-17A and IL-17F are also key 
cytokines for the recruitment, acti vati on and migrati on of neutrophils. Furthermore, they 
have also been reported to be important in host defense against bacterial infecti ons in 
mice.
IL-17A and F in autoimmunity
Already in 1998, Teunissen and colleagues described the upregulati on of IL-17A in psoriati c 
skin (124) and since then potenti al roles of this cytokine in other autoimmune diseases 
like CIA, IBD, MS and EAE have been suggested. For example, abrogati on of IL-17A prior to 
disease onset mildens anti gen-induced arthriti s in mice and treatment with neutralizing 
anti bodies aft er disease onset decreases joint damage (125,126). Recently, IL-17 has also 
been demonstrated to regulate auto-anti body producti on (127). IL-17A defi cient mice 
or mice treated with an IL-17R antagonist develop reduced adjuvant-induced arthriti s 
(125,128) but are suscepti ble to EAE, albeit with a delayed onset and reduced severity. 
Even though more and more data indicate that IL-17 cannot be the most important 
cytokine in EAE or MS, many reports suggesti ng IL-17 to be a key player in these diseases 
have accumulated during the recent years. IL-17A was described to be upregulated in 
CNS lesions of pati ents with MS (129), neutralizati on of IL-17 reduces the severity of EAE 
(99) and, as menti oned above, IL-17A-defi cient mice show delayed onset and reduced 
maximum-severity scores in EAE (130). Furthermore, EAE could be induced aft er transfer 
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of in vitro polarized TH17 cells (101).
Taken together, IL-17 certainly seems to play a pathological role in many autoimmune 
diseases, although it is very unlikely to be the only eﬀ ector cytokine in autoimmunity. 
Eﬃ  cacy, safety and tolerability studies with a monoclonal anti -IL-17 anti body (AIN457) 
are currently carried out in Crohn’s disease (CD) and psoriasis that are resistant to current 
therapies and the results of these clinical trials will clearly give new insights in the 
contributi ons of IL-17 to these diseases (102).
IL-22
IL-22 was fi rst described in 2000 as an IL-9 induced gene and termed “IL-10 related T cell-
derived inducible factor” (IL-TIF). Together with IL-19, IL-20, IL-24 and IL-26 it belongs to 
a family of cytokines structurally related to IL-10 (131). The IL-22 gene was mapped near 
the IFN-γ gene on chromosome 10 in mice and on chromosome 12 in humans. Unlike in 
humans or the genomes of BALB/c and DBA/2 mice, genomes of other mouse strains such 
as C57Bl/6, FVB and 129 possess two IL-22 genes, designated IL-22 α and β. The murine 
IL-22β gene contains several single nucleoti de changes and a 658 nucleoti de deleti on 
covering the fi rst noncoding exon and a segment of a putati ve promoter, suggesti ng that 
the IL-22 β gene may not be expressed (132). 
IL-22 signals through a class II cytokine receptor complex composed of two chains - IL-
22R1 and IL-10R2. IL-22R1 is also uti lized by IL-20 and IL-24 and IL-10R2 is shared with IL-
10, IL-28 and IL-29. The expression of IL-22R1 could only be detected in a limited number 
of ti ssues such as skin, liver, lung, kidney and pancreas, whereas cells of the immune 
system do not express IL-22R1 even under sti mulated conditi ons (133). Concordantly, IL-
22 failed to sti mulate immune cell functi ons such as cytokine secreti on and surface marker 
expression but elicited very strong responses from many epithelial cells or cell lines, 
including acinar cells, hepatocytes, kerati nocytes and colon epithelial cells (131,134,135). 
In additi on to the cell surface IL-22 receptor complex, a soluble single chain IL-22 receptor 
exists, termed IL-22 binding protein (IL-22BP), which antagonizes IL-22 cellular binding 
and signaling in vitro (136). The signaling of IL-22 following binding to its receptor includes 
acti vati on of JAK1 and Tyk2 tyrosine kinases, which leads to STAT3- and, to a lesser extent, 
to STAT1- and STAT5-phosphorylati on. IL-22 was also found to acti vate the ERK, JNK and 
p38 MAPK in the rat hepatoma cell line H4IIE.
Wolk et al. have shown that in peripheral blood mononuclear cells (PBMCs), the major 
source of IL-22 are acti vated (memory) T cells, especially upon TH1 polarizati on and NK 
cells (137,138).
However, soon aft er the characterizati on of TH17 cells it became clear, that this T cell 
subtype is the dominant IL-22 producer, as demonstrated at both the mRNA and protein 
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levels and now it is clearly established that IL-22 is another eﬀ ector cytokine produced by 
TH17 cells (139). Additi onally, IL-22 secreti on in monocytes and CD11c
+ DCs as well as CD8+ 
T cells and γ/δ T cells aft er IL-23 sti mulati on has been reported (140,141). IL-22 drives the 
producti on of many anti microbial pepti des, including β-defensins, S100-family proteins 
and regenerati ng-gene (Reg)-family proteins and protects against extracellular bacterial 
pulmonary and enteric infecti ons (142-144).
IL-22 in autoimmunity
The fi rst evidence of a role of IL-22 in autoimmunity stems from observati ons made 
in psoriasis, as IL-22 is upregulated in psoriati c skin (145) and induces many psoriati c 
features in cultured reconsti tuted human epidermis in vitro. (146). Aft er injecti on of IL-23 
into the ear, an infl ammatory skin phenotype with IL-22 and IL-17 expressing TH17 cell 
infi ltrati on and epidermal acanthosis is induced (140) and diminished in IL-22-defi cient 
mice. Furthermore, the infl ammatory skin disease in a murine model of psoriasis is 
ameliorated aft er IL-22 anti body treatment (147). 
An upregulati on of IL-22 has also been described in autoimmune diseases like CD 
and ulcerati ve coliti s (UC), as well as in preclinical mouse IBD models or RA pati ents 
(135,148). 
In additi on to its proinfl ammatory role, protecti ve functi ons of IL-22 have also been 
described. For example, IL-22 protects the liver injury by enhancing the growth and survival 
of hepatocytes (149). Studies with both IL-22- and IL-17-defi cient mice further supported 
a protecti ve functi on of IL-22 (150) and IL-22 has been shown to be protecti ve in a rat 
model of experimental autoimmune myocarditi s (151). In conclusion, both pathogenic 
and protecti ve functi ons of IL-22 in autoimmune diseases have been observed, depending 
on the specifi c situati ons and target cells.
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Abstract
The clear associati on of the TH17 phenotype with autoimmune pathogenicity 
implicates TH17 cytokines as criti cal mediators of chronic autoimmune diseases such as 
experimental autoimmune encephalomyeliti s (EAE). To study the actual impact of IL-17 
on CNS infl ammati on, we generated transgenic mice in which the expression of high 
levels of IL-17A can be initi ated by cre-recombinati on. While the general overexpression 
of IL-17A leads to skin infl ammati on and granulocytosis, T cell driven IL-17A expression 
does not impact visibly on the development and health of the mouse. In the context of 
EAE, here we demonstrate that neither the T cell-driven overexpression of IL-17A nor 
its complete loss have a signifi cant impact on the development of clinical disease. Since 
TH17 cells also produce IL-17F, which evidently acts through the same receptor complex 
as IL-17A, it is feasible that it could compensate for the loss of IL17A in IL-17Anull mice. 
To determine the actual functi on of IL-17F in autoimmune infl ammati on of the CNS, we 
next generated IL-17Fnull mice. They not only lack IL-17F, but also produce signifi cantly 
less IL-17A. Nevertheless, they too are fully EAE suscepti ble and display unaltered 
emergence, expansion and polarizati on of auto-reacti ve T cells during EAE. We conclude 
that IL-17A and IL-17F, while prominently expressed by encephalitogenic T cells, do not 
or only marginally contribute to the development of autoimmune CNS-disease.
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Introduction
Multi ple sclerosis (MS) and its animal model EAE are characterized by the invasion of 
self-reacti ve TH cells into the CNS, leading to demyelinati on, axonal loss and neurological 
impairment (152). Upon acti vati on, TH cells can diﬀ erenti ate into diﬀ erent eﬀ ector cells, 
depending on the makeup of the priming immune synapse as well as the cytokines present 
(153). For over a decade, IFN-γ secreti ng TH1 cells were thought to be the pathogenic 
populati on central to the pathogenesis of autoimmunity, reasoned by the clear associati on 
of the TH1 eﬀ ector type to diseases like rheumatoid arthriti s, multi ple sclerosis and type I 
diabetes. In their respecti ve animal models, however, the loss of the major TH1 cytokines, 
IFN-γ, IL-12 and IL-18 surprisingly did not hamper disease development (76,78,154). In 
fact, IFN-γ and IL-12 defi ciency lead to clinically even more severe infl ammati on in CIA 
and EAE (76,78,96). With these discoveries the simplisti c noti on that TH1 cells and their 
respecti ve cytokines are the culprits of autoimmunity had to be revised. In contrast to 
IL-12, its relati ve IL-23 was found to be essenti al for the development of EAE and CIA 
(99). The fi nding that IL-23 induces the expression of IL-17A by TH cells then gave rise 
to the noti on that not TH1, but IL-17A secreti ng TH cells (TH17) are the main pathogenic 
populati on in autoimmune diseases (155). The respecti ve hypothesis was strongly 
supported by adopti ve transfer models, in which the transfer of IL-17A producing eﬀ ector 
cells into wild type hosts resulted in the initi ati on of autoimmunity (156). The de novo 
lineage commitment of naïve T cells towards IL-17A secreti on is dependent on TGF-βR 
engagement whereas IL-6 has been identi fi ed as a diﬀ erenti al co-sti mulus directi ng cell 
fate towards TH17committ ment (109). IL-17A secreti on is considered the hallmark of TH17 
functi on, as it exhibits strong pro-infl ammatory properti es (157) and is widely held as 
being the major driving force in the pathogenesis of autoimmunity. Despite the plethora 
of data published on IL-17A, implicati ng its functi on in physiological processes, hardly 
any studies reveal a true causati ve associati on. Here, we have generated mice in which 
specifi cally T cells overexpress IL-17A regardless of their state of acti vati on and found 
that even massively increased levels of IL-17A producing cells in the infl amed CNS has 
no impact on the pathogenesis of EAE. Also, we confi rmed that IL-17A-/- mice are fully 
suscepti ble to EAE. It is feasible that other TH17 cytokines can compensate for the loss 
of IL-17A. The closest associate to IL-17A is IL-17F and (158,159) is encoded syntenically, 
shares around 50% sequence homology and a virtually identi cal patt ern of expression with 
IL-17A (160). IL-17A/F heterodimers were described (161) and shown to signal through 
the same receptor complex (120). In order to determine whether IL-17F contributes to the 
pathogenicity of TH17 cells, we generated IL-17F
null mice and explored their suscepti bility 
to EAE. We found that in additi on to lacking IL-17F, they express lower levels of IL-17A. 
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Surprisingly however, we discovered IL-17F-/- mice also to be fully suscepti ble to EAE, 
indicati ng that, while TH17 cells associate with an encephalitogenic phenotype, neither 
IL-17A nor IL-17F appear to contribute to the pathogenic functi on of TH17 cells in vivo.
Results
Transgenic targeting of IL-17A to T cells does not alter the pathogenesis and 
clinical development of MOG-induced EAE.
To address the impact of IL-17A expressed by CNS invading T cells on the pathogenesis of 
EAE, we generated a mouse conditi onally overexpressing IL-17A and EGFP aft er excision 
of a loxP-fl anked transcripti onal STOP-cassett e (termed IL-17Aind) (Supplemental Fig.1). In 
order to verify the functi on of the transgene, IL-17Aind were crossed with the cre-deleter 
strain. These mice show early signs of skin infl ammati on and ulti mately a developmental 
retardati on clearly visible from P4-6 on, as can be seen in Supplemental Figure 2 A. On the 
cellular level the IL-17A overexpression (Suppl. Fig. 2 B) leads to a massive increase in the 
number of granulocytes throughout the body, especially in bone marrow, spleen and blood 
(Suppl. Fig. 2 C-D). Chemical analysis of the blood compartment revealed an anaemia-like 
phenotype which can be expected to accompany granulocytosis (Suppl. Fig. 2 E). We are 
in the process of further elucidati ng the clinical impact of this genotype (manuscript in 
preparati on). Crossing the IL-17Aind to CD4-Cre expressing mice (CD4-IL17Aind) generated 
a T cell repertoire in which only T cells express IL-17A and EGFP (Supplemental Fig.1 D 
and Fig.1 A). Expression of IL-17A by T cells in CD4-IL17Aind/+ mice did not result in an 
overt phenotype neither in the macroscopic consti tuti on of the mice nor in the cellular 
compositi ons of thymus, 
spleen and lymph nodes 
(Supplemental Fig.1 D 
and data not shown). To 
verify the increased IL-17A 
secreti on we performed IL-
17A-specifi c ELISA assays 
with FACS-sorted CD4-
IL17Aind/+ and IL-17Aind/+ 
CD4+ T cells 48 h aft er 
sti mulati on by CD3 and 
CD28 cross-linking. As 
Table I:   Detailed clinical development of EAE in IL-17A over-
expressing, IL-17A and IL-17F defi cient mice.
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expected, CD4-IL17Aind/+ CD4 T cells produce and secrete highly elevated levels of IL-17A 
compared to IL-17Aind/+ T cells, where overexpression of the cytokine is not induced (Fig. 3 
B). Next, we immunized CD4-IL17Aind/+ mice with MOG35-55/CFA and followed the onset and 
progression of EAE. Surprisingly, no signifi cant clinical diﬀ erences were observed between 
CD4-IL17Aind/+ and IL-17Aind/+ litt ermates (Fig. 3 C and Table I). Consistent with the clinical 
disease cellular CNS invasion was virtually identi cal in both groups as measured by fl ow 
cytometry (data not shown). From all CNS fracti ons analyzed no signifi cant alterati ons 
were observed with respect to IFN-γ secreti ng cells (Fig. 3 D). However, CNS extracts from 
CD4-IL17Aind/+ mice presented with a clearly identi fi able and highly signifi cant increase 
in IL-17A+ T cells compared to IL-17Aind/+, despite indisti nguishable clinical scores. Taken 
together, an increase in T cell derived IL-17A in the infl amed CNS during MOG-induced 
EAE does not result in an appreciable alterati on of the disease course.
Figure 3:  IL-
17A overex-
pression does 
not exacerbate 
EAE.
(A) Splenocytes 
from naive CD4-
IL17Aind/+ and 
IL-17Aind/+ lit-
termates were 
r e s t i m u l a t e d 
in culture and 
s u b s e q u e n t l y 
stained for CD4 
and IL-17A. 
Percentages of 
EGFP+IL-17A+ or 
EGFP+IFN-γ+ CD4+ 
T cells are given 
in the quadrant 
corners aft er 
gati ng on CD4+ T 
cells. Data shows 
a representati ve 
of three inde-
pendent experi-
ments. (B) 1x105 FACS-sorted CD4+ T cells were cultured for 36 h in the presence or absence of 
anti -CD3 and anti -CD28, aft er which IL-17A secreti on was measured by ELISA. (C) Clinical scores 
aft er MOG35-55-induced EAE are not signifi cantly altered by increased IL-17A expression in CD4-
IL17Aind/+ and IL-17Aind/+ litt ermates.  Error bars represent +/- SEM. Data shown represents one 
out of two independent experiments. (D) Lymphocytes isolated from the diseased EAE brain and 
spinal cord at d 14 from CD4-IL17Aind/+ and IL-17Aind/+ litt ermates were surface stained for CD4 and 
examined for EGFP-expression. Further staining for CD4, IL-17A and IFN-γ was performed. Per-
centages of EGFP+IL-17A+ or EGFP+IFN-γ+ are given in the quadrant corners. Plots shown are gated 
on CD4+ CNS-derived T cells.
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IL-17A function is redundant in the development of EAE
In order to improve the understanding of the role of the TH17 eﬀ ector type in autoimmunity 
we next analyzed the impact of loss of IL-17A on the autoreacti ve TH17 response in EAE. 
Despite the close associati on of IL-17A with the infl ammatory milieu in EAE, the loss of 
IL-17A does not fundamentally impede the inducti on of the disease, which is similar to 
the observati ons made by Iwakura and colleagues (130) (Fig. 4 A). In the course of EAE, 
shown in Fig. 4 A, there is an apparent mild decrease of disease severity. Overall, the IL-
17A defi cient mice are stati sti cally less severely sick (ANCOVA, P=0.015). However, the 
diﬀ erence in the course of the disease between wildtype and IL-17A defi cient mice accounts 
for only 1.6 % of the variance in the experiment, which enumerates how small the eﬀ ect 
size is compared to the variance in the system (e.g. the “mouse identi ty” accounts for 24 
% of the variance). In a detailed analysis of the pooled data, we observed only a minimal 
yet stati sti cally signifi cant (two-tailed t-test, p=0.013) diﬀ erence in the day of onset of 
disease and an insignifi cant decrease 
in incidence and the maximal severity 
of disease (Table I). The non-essenti al 
role of IL-17A in EAE development may 
be due to the involvement of other 
TH17 associated factors. To elucidate 
the quality of the TH17 response in 
the immunized IL-17A defi cient mice 
Figure 4:  IL-17A is redundant in the 
inducti on of EAE which could be due 
to a compensatory increase of IL-17F 
producti on. 
(A) EAE was induced in IL-17A−/− and IL-
17+/+ mice by immunizati on with MOG35-55/
CFA. The graph shows the development 
of EAE according to clinical scores (n=10, 
SEM as indicated) in one out of two inde-
pendent experiments. (B) TH17-cytokine 
profi le measured by ELISA of splenocytes 
isolated from mice with acti ve EAE and 
resti mulated with MOG35-55 under TH17 
polarizing conditi ons for 2 days. (C) Com-
parati ve mRNA expression analysis of IL-
17F and -17A in the cerebellum of mice at 
peak EAE vs. healthy controls, HC. The data 
represents one of two independent experi-
ments (n=4). (D) TH17 cells were generated 
in vitro from MOG35-55-immunized C57BL/6 
mice. Seven dpi splenocytes were harvest-
ed, TH17-polarized and analyzed by intrac-
ellular cytokine staining for IL-17A, IL-17F 
and IFN-γ. Shown is a representati ve of 
three independent experiments.
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we analyzed their cytokine secreti on upon in vitro resti mulati on with MOG35-55 pepti de 
under TH17 polarizing conditi ons (Fig. 4 B) or under the infl uence of IL-23 alone (data not 
shown). Surprisingly, while the IL-22 levels were equal in T cells obtained from IL-17A 
defi cient and wild type control mice, IL-17F secreti on was found to be consistently and 
drasti cally increased in the lymphocytes of IL-17A defi cient mice. This specifi c increase 
of one TH17 cytokine suggests the possibility of a compensatory role of IL-17F in disease 
development.
IL-17F is expressed by TH17 cells and is abundant in the inflamed CNS 
A screen performed by quanti tati ve RT-PCR of cerebellum of mice with acti ve EAE 
revealed that IL-17F like IL-17A is highly expressed in the lesioned CNS as compared to 
cerebellum of healthy controls (Fig. 4 C). To assess the source of IL-17F in the context 
of EAE we resti mulated in vivo primed splenocytes in vitro with MOG35-55 under TH17 
polarizing conditi ons and subsequently analyzed the cytokine profi le by intracellular 
cytofl uorometric analysis. Figure 4 D shows that IL-17F expression is restricted to MOG-
Figure 5:  IL-17F is not required for the development of EAE. 
(A) EAE was induced in IL-17F−/−, −/+ and +/+ mice by immunizati on with MOG35-55/CFA. The graph 
shows the development of EAE according to clinical scores in one out of fi ve independent ex-
periments. (B) Spinal cord cross-secti ons in accordance with clinical EAE scores displayed similar 
infl ammatory lesions (H&E staining, 1st and 2nd column, arrows). Infl ammati on caused an impair-
ment of myelinated structures (staining for CNPase, 4th column) and induced a reacti ve astroglio-
sis (staining for GFAP, 3rd column). All stainings were performed on serial secti ons. Scale bars: 500 
μm for 1st, 50 μm for 2nd, 3rd and 4th column. Insert in 1st column represents the area shown in 2nd, 
3rd and 4th column. (C) Detailed analysis of infi ltrati ng lymphocytes into cerebellum and spinal cord 
was performed by cytofl uorometric analysis of surface marker staining. CD45high cells represent 
the CNS-invading leukocytes which were gated on for detailed analysis. 
A B
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responsive and potenti ally encephalitogenic 
CD4+ TH cells that are also secreti ng IL-17A.
The fi ndings that both cytokines are found 
in the infl amed CNS and mark those highly 
pathogenic TH17 cells that have been 
associated with autoreacti ve lesions suggests 
that IL-17F is a encephalitogenic cytokine 
with functi onal relevance in CNS autoimmune 
infl ammati on.
Generation and analysis of the IL-17F deficient mice
To ulti mately determine whether IL-17F contributes to the development of EAE, we 
generated IL-17F defi cient mice by the replacement of exons 2 and 3 with a lacZ reporter 
cassett e (Supplemental Fig. 1). In the following experiments IL-17F defi ciency was confi rmed 
by ELISA (Supplemental Fig. 1). The homozygous oﬀ spring is viable and shows neither 
developmental malformati on nor any evident immunodefi ciency under SPF conditi ons. 
There are no apparent alterati ons in the cellular compositi on of the immune system in 
homeostasis as is shown by FACS analysis for spleen and thymus in Supplemental Table 1. 
Up to 42 mice per group (+/+, +/−, −/−) in 6 independent experiments were immunized 
with MOG35-55/CFA and the clinical development of EAE was monitored daily. Against our 
expectati ons, the lack of IL-17F did not have any visible consequences for the clinical EAE 
development as shown in Figure 3 A. IL-17F-/- mice did not show any alterati on in the day 
Figure 6: Loss of IL-17F does not impact on 
T cell proliferati on upon TH cell priming and 
does not lead to a compensatory upregula-
ti on of IL-17A. 
(A-C) Mice were immunized with MOG35-55/CFA 
and lymphocytes isolated from LN prior to dis-
ease onset on 7 dpi. Cells were rechallenged with 
50μg/ml of MOG35-55 and IL-17A and IL-2 was 
measured by ELISA (A) and ELISPOT (B). (C) Prolif-
erati on of eﬀ ector TH cells was measured by thy-
midin incorporati on. (A-C) Shown is a representa-
ti ve of at least three independent experiments. 
Error bars indicate SEM of measured replicates. 
(D) Splenocytes from naive mice were polarized 
towards the TH17 eﬀ ector type in vitro and IL-
17A, IL-17F and IFN-γ was measured by intracel-
lular cytokine staining. Dot plots are gated on TH 
cells (CD4+), histograms are gated on TH17 cells 
(CD4+, IL-17A+).
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of disease onset, maximum score or incidence when compared to IL-17F competent (+/+, 
+/−) mice (Table I). In accordance with clinical EAE scores, histological analysis of spinal cord 
cross-secti ons displayed no discernable features between wild type mice and hemizygous 
IL-17F+/- and/or homozygous IL-17F-/- mice. Infl ammati on caused a severe impairment of 
myelinated and axonal structures, subsequently inducing reacti ve astrogliosis (Fig. 5 B). 
Detailed analysis of CNS-infi ltrati ng cells by fl ow cytometry revealed no change in cell 
numbers or makeup of CNS invading leukocytes (Fig. 5 C). 
We did not observe any relevant diﬀ erence in the capacity of IL-17F-/- mice to initi ate CD4 
T cell priming and the eﬀ ector T cell response. IL-17F-/- and control mice were immunized 
against MOG35-55 and primed lymphocytes were isolated from draining LN prior to disease 
onset (Fig. 6 A-B) and were subsequently challenged in vitro with their cognate anti gen. 
Lymphocytes from all groups responded with the same degree of proliferati on (Fig. 6 C). 
The full suscepti bility of IL-17F-/- mice to EAE could have resulted from a compensatory 
increase in the producti on of IL-17A. However, IL-17F-/- lymphocytes showed a consistent 
decrease in the producti on (Fig. 6 A) and frequency (Fig. 6 B) of IL-17A secreti ng cells. 
Even upon overwhelming in vitro polarizati on towards the TH17 lineage the proporti on of 
IL-17A producing cells as much as the amount of cytokine produced decreases drasti cally 
in IL17F-targeted cells, when compared to wild type T cells (Fig. 4 D-E). While our data 
indicate some degree of haplo-insuﬃ  ciency of the IL-17F allele (Fig. 6 E and Supplemental 
fi g. 1 E), targeti ng this locus has a profound inhibitory impact on IL-17A expression. 
Discussion
Aft er the discovery of disti nct T cell polarizati on patt erns by Mosmann and colleagues 
(162), it was accepted for more than a decade that IFN-γ secreti ng TH1 cells are the 
main encephalitogenic populati on in CNS infl ammatory diseases such as MS and EAE. In 
additi on, TH1 promoti ng factors such as IL-12 and IL-18 were considered indispensable for 
the initi ati on of autoimmune disease in mice. This simplisti c paradigm had to be revised 
when it was discovered that mice defi cient in IFN-γ, TNF-γ, IL-12p35 and IL-18 are either 
fully EAE-suscepti ble or hyper-suscepti ble. While IL-12 is dispensable for the inducti on of 
EAE, its close relati ve IL-23 has been demonstrated to be absolutely essenti al. Langrish 
et al. initi ally were able to show that IL-23 induces the secreti on of IL-17A by eﬀ ector T 
cells (156). IL-17A secreti ng eﬀ ector T cells were ulti mately termed TH17 cells and are now 
established as a disti nct helper T cell subset. In additi on, the close associati on of TH17 cells 
with infl ammatory autoimmune diseases such as RA, MS and psoriasis has clearly marked 
this populati on as pathogenic (155). Several reports have then elucidated the conditi ons 
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to polarize towards this lineage in vitro (109,155). 
While IL-17A is now considered to be the main driving force behind ti ssue infl ammati on, to 
this day, virtually all claims are based on a correlati ve relati onship between TH17 cells and 
their presence in an infl ammatory lesion. Assuming that IL-17A drives the infl ammatory 
process and could contribute to blood brain barrier breakdown and increased detrimental 
neutrophil acti vity, we generated transgenic mice in which T cells produce high levels 
of IL-17A. Surprisingly however, drasti cally increased levels of IL-17A expression neither 
visibly impact on the development of EAE nor on the quality and quanti ty of infl ammati on 
in the CNS. Komiyama et al. previously addressed the role of IL-17A in EAE by generati ng 
a defi cient mouse strain (130). Unlike the defi ciencies in IL-23 and IL-6 which render mice 
completely resistant to EAE, loss of IL-17A only marginally impacts on the severity of 
disease. The far more criti cal role of IL-23 and IL-6 in the development of autoimmune 
infl ammati on indicates that the associated disrupti on of IL-17A and -17F producti on is a 
symptom but not the cause of the EAE resistance observed in IL-23 and IL-6-defi cient mice. 
Matching our conclusions, also in other models of autoimmunity such as experimental 
autoimmune uveoreti niti s (EAU), the functi on of IL-17A appears to be redundant (163). 
Luger et al. recently demonstrated that while IL-17 can parti cipate in the pathogenesis of 
EAU, it has by no means an essenti al role (164). The concept that IL-17A itself is not likely 
the only pathogenic molecule generated by TH17 cells was further supported by the report 
of McGeachy et al., who could demonstrate that IL-23 driven TH cells, but not TGF-β/IL-6 
driven TH cells were encephalitogenic, regardless of their secreti on of IL-17A (115).
By now, a whole family of new cytokines has been grouped around IL-17A, all sharing a 
disti nct structural feature, a 4-cystein knot (165). The closest associate to IL-17A is IL-17F 
(158,159). Both cytokines are functi onally related to neutrophil recruitment and expansion, 
angiogenesis, ti ssue remodeling and the inducti on of pro-infl ammatory factors, like IL-1β, 
TNF-α, chemokines and defensins (139,157,166).  
We found that the loss of IL-17A coincides with a signifi cantly elevated level of IL-17F 
expression, making IL-17F an ideal candidate to compensate for the loss of IL-17A in gene-
targeted mice. We generated IL-17F defi cient mice and discovered that they are also fully 
suscepti ble to EAE and have no appreciable defect in generati ng an infl ammatory response. 
One could argue conversely, that in IL-17F-/- mice IL-17A could compensate and that the 
true functi on of IL-17A and IL-17F can only be appreciated in mice lacking both genes. 
Unfortunately, the close proximity of the loci of these two cytokines makes it virtually 
impossible to obtain double-defi cient mice by mere interbreeding (ca. 44 Kb in between 
the two genes). However, while IL-17A-/- T cells have the propensity to secrete much more 
IL-17F upon acti vati on, our IL-17F-targeted T cells make signifi cantly less IL-17A than wild 
type mice, which was also observed in a diﬀ erent IL-17F defi cient mouse strain, generated 
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by inserti on of an transcripti onal stop into exon 2 (167). Our current hypothesis is that 
either the gene-targeti ng of IL-17F interferes with the promoter/enhancer acti vity of IL-
17A or that IL-17F exerts some kind of regulatory eﬀ ect on IL-17A producti on In any case, 
the fact that IL-17F-/- mice show this drasti c reducti on in IL-17A strongly supports the noti on 
that neither IL-17A nor IL-17F, either individually or in combinati on, are essenti al for the 
development of autoimmune CNS infl ammati on. In additi on, the fact that mice in which 
transgenic overexpression of IL-17A is directed towards T cells also display an unaltered 
EAE phenotype, further eliminates IL-17A as an important player in CNS-autoimmunity. 
Considering that IL-17A, as a pro-infl ammatory cytokine, is produced in large amounts 
at sites of infl ammati on in the brain and elsewhere it is expected to fi nd some degree of 
symptomati c att enuati on. Integrati ng all current data generated by deleti on of IL-17A as 
much as IL-17F and IL-22 or induced overexpression of IL-17A by criti cal evaluati on of its 
stati sti cal vs. biological relevance we must conclude that, unlike IL-23, none of those TH17 
cytokines are key players in autoimmune disease like EAE.
The mere presence of a pro-infl ammatory molecule at the infl ammatory site is oft en 
interpreted to convey a vital functi on ulti mately to be translated into an att racti ve drug 
target. However, while we can clearly confi rm that IL-17F has all the features of such 
a factor, in vivo targeti ng shows that this correlati on is not in fact causati ve. While IL-
17 family member molecules currently serve their purpose as markers for pathogenic 
self-reacti ve cells, we conclude that other, thus far unidenti fi ed factors or mechanisms 
employed by TH17 cells must convey their pathogenic capacity. Alternati vely, it is also 
possible that TH17 cells harbor a small populati on of IL-23-driven T cells which possess 
all the pathogenic potenti al, and that TH17 cells have gained their place in the spotlight 
based upon the concept “guilty by associati on”.
Materials and Methods
Mice
Female C57BL/6 mice were purchased from Harlan Laboratories. IL-17A-/- mice were 
generously provided by Dr. Yoichiro Iwakura (University of Tokyo, Japan). IL-17F-/- 
(129xC57BL/6) and IL-17Aind/+ mice were generated as described in Supplemental Figure 
1. Animal experiments were approved by the Swiss Veterinary Oﬃ  ce (13/2006, Zurich, 
Switzerland) and the Central Animal Facility Insti tuti on of the University of Mainz. EAE 
inducti on and monitoring of disease severity was performed as previously described 
(154). 
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In vitro assays
Lymphocytes were cultured in RPMI1640 containing 10% FCS (both from Invitrogen). 
Resti mulati on of primed lymphocytes from lymph node, spleen or cerebellum was 
measured on 7 (pre-EAE) dpi by MOG35-55/CFA (154) and challenged with 50μg/ml  MOG35-55 
or 5μg/ml ConA. Proliferati on was assessed by thymidin incorporati on (168) and cytokine 
release by ELISA (BD Pharmingen) and ELISPOT (154) as described.  Acti vati ng anti -CD3 
and anti -CD28 anti bodies used in concentrati on of 1μg/ml and 6ng/ml, respecti vely. 
Fluorocytometric analysis of surface marker expression was performed as described (36). 
Intracellular cytokine staining was performed with the Cytofi x/Cytoperm™ Plus Kit (BD 
Bioscience) according to manufacturer’s directi ons. Anti bodies used: anti -IL-17A (TC11-
18H10), anti -IFN-γ (XMG1.2) (BD Pharmingen) and anti -IL-17F (R&D Systems). The IL-
17F anti body was labeled using the Alexa Fluor® 488 Monoclonal Anti body Labeling Kit 
(Invitrogen).
T cell polarization
For the in vitro generati on of TH17 cells, splenocytes were harvested 7 dpi with MOG/CFA 
and were resti mulated with 20 μg/ml MOG35-55 , 5ng/ml TGF-β, 20 ng/ml IL-6 (both from 
PeproTech EC, UK), 10 ng/ml IL-23 (R&D Systems), 5 μg/ml anti -IFNγ (R4-6A2) (Bioexpress) 
and 5 ng/ml IL-2 (eBioscience). Anti -IFN-γ was added daily, IL-23 on day 0 and 2. Cells 
were analysed on day 6 post culture.
Real-time RT-PCR
RNA was extracted and cDNA prepared as described. The primers used for IL-17F were: 
fw: CTGTTGATGTTGGGACTTGCC and rev: TCACAGTGTTATCCTCCAGG . β-acti n and IL-17A 
primers were described elsewhere (154).
Histology and immunohistochemical staining
Spinal columns were fi xed in 4% paraformaldehyde in PBS, paraﬃ  n-embedded, 
cut and stained with hematoxylin-eosin (H&E) according to standard protocols. 
Immunohistochemical stainings on serial secti ons using anti bodies to CNPase (1:500, 
Chemicon) and glial fi brillary acidic protein (GFAP, 1:4000, DAKO) were carried out on 
an automated Benchmark staining apparatus (Ventana Medical Systems), following the 
manufacturer’s guidelines.
Extracti on of mononucleated cells from infl amed CNS ti ssue and subsequent 
cytofl uorometric analysis was performed as described previously (36).
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Statistical analysis
Clinical development was evaluated using a two-tailed Student’s T test as well as ANCOVA 
analysis using the R project for stati sti cal computi ng.  
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Supplemental Figure 1:  Generati on of the IL-17A overexpressing and IL-17F defi cient 
mouse strains. 
(A) Generati on of the IL-17Aind/+ allele was carried out using homologous recombinati on in em-
bryonic stem cells (C57BL/6-Bruce 4). Our conditi onal ‚knock-in’ approach introduced the target-
ing construct into the endogenous gt(ROSA)26Sor locus. Upon Cre-mediated recombinati on, a 
lox-P-fl anked transcripti onal STOP cassett e is excised 5’ of an IL-17A CDS insert and an IRES-EGFP 
element, allowing a dual expression of IL-17A and EGFP under the control of the chicken β-acti n 
(CAG) promoter. (B) 1x106 whole lymph node cells from IL-17Aind/+ mice were cultured for 4 h with 
or without (data not shown) Tat-Cre protein to induce IL-17A and EGFP expression in the pres-
ence of anti -CD3, anti -CD28 and IL-2. Aft er 36 h, cells were briefl y cultured with Brefeldin A and 
stained for CD4 and either IL-17A or IFN-γ. Percent-
ages of IL-17A+EGFP+ and IFN-γ+EGFP+ cells are given 
in the quadrants. No EGFP was detected in wild type 
mice also treated with Tat-Cre (data not shown). (C) 
LN cells were cultured as in B, and supernatants ex-
tracted aft er 36 h. IL-17A secreti on was measured by 
ELISA. (D) EGFP expression was measured in T cells 
populati ons aft er crossing the IL-17Aind allele to the 
CD4 Cre transgene. EGFP expression was clearly de-
tectable in CD90+ splenocytes from CD4-IL17Aind/+. No 
EGFP was detectable in IL-17Aind/+ litt ermates. (E) IL-
17F gene-targeti ng strategy for the generati on of the 
IL-17F-defi cient mouse strain. A reporter gene/resis-
tance cassett e (lacZ gene and a Ub1-Em7 promoter 
driven neomycin resistance gene, neo, fl anked by 
loxP sites) was introduced into il17f exon 2 and 3 of 
a BAC containing the IL-17F gene locus. 129S6SvEv/
C57B/6F1 embryonic stem cells were targeted with a 
BAC carrying the replaced il17f gene locus and were 
subsequently screened as described elsewhere (28). 
“a” and “b” represent amplicons for the wt and tar-
geted allele respecti vely. Complete loss of IL-17F in 
the IL-17null mouse was confi rmed by ELISA on super-
natant of TH17 polarized splenocytes.
Supplemental Table I:   Homeo-
stati c leukocyte compositi on in 
spleen and thymus of naïve IL-
17F defi cient and control mice.
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Supplemental Figure 2:  Del-IL-17Aind mice display increased granulocyte producti on 
and accumulati on. 
(A) (Del = Deleter Cre, and Del-IL-17Aind =Deleter Cre x IL-17Aind mice) Mice of two weeks of age 
from Del-IL-17Aind versus Del control present with stunted growth, thin coats, psoriati c skin and 
blindness.  (B) 1x106 cells from bone marrow (BM) and spleen (SPL), and 2.5x105 cells from me-
senteric lymph nodes (MLN) and thymus (THY) were cultured for 24h in cell culture medium the 
absence of any sti mulati on.  Resulti ng supernatants were assayed for IL-17A secreti on by ELISA. 
Error bars represent SEM. (C) Bone marrow (BM) from 4 week old Del-IL-17Aind mice was stained 
using anti -GR1 and anti -CD11b and analysed by FACS.  Percentages are given in the representati ve 
quadrant, and represent 6 mice in three independent experiments. (D) Spleen (SPL) and blood 
(BL) samples from Del-IL-17Aind and litt ermate control mice were stained with anti bodies directed 
against GR-1 and MHC-class II. Percentages are given in the representati ve quadrants, and repre-
sent either 8 mice in three independent experiments (SPL) or 5 mice in two separate experiments 
(BL). (E) Blood analysis of three Del-IL-17Aind and Del control mice. Stati sti cal analysis of the aver-
ages by Student’s t-test.
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Abstract
Lately, IL-17 secreti ng TH cells received an overwhelming amount of att enti on and are 
now widely held to be the major pathogenic populati on in autoimmune diseases. In 
parti cular IL-22 secreti ng TH17 cells were shown to specifi cally mark the highly pathogenic 
populati on of self-reacti ve T cells in experimental autoimmune encephalomyeliti s (EAE). 
As IL-17A itself was found to only play a minor role during the development of EAE, IL-22 
is now postulated to contribute to the pathogenic functi on of TH17 cells. The goal of this 
study was to determine the role and functi on of IL-22 during the development of CNS 
autoimmunity in vivo. We found that CNS-invading encephalitogenic TH17 cells coexpress 
IL-22 and that IL-22 is specifi cally induced by IL-23 in autoimmune-pathogenic CD4+ T 
cells in a ti me- and dose-dependent manner. We next generated IL-22-/- mice, which - in 
contrast to the predicti on that expression of infl ammatory cytokines by CNS-invading T 
cells inevitably confers pathogenic functi on – turned out to be fully suscepti ble to EAE. 
Taken together, we show that self-reacti ve TH cells coexpress IL-17 and IL-22, but that 
the latt er also does not appear to be directly involved in autoimmune pathogenesis of 
the CNS. 
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Introduction
Multi ple sclerosis (MS) is the most common infl ammatory disease of the CNS and its 
animal model EAE is mediated by the acti ons of auto-reacti ve encephalitogenic TH cells. 
While TH1 cells were long suspected to be the major pathogenic populati on, the discovery 
that IL-23 and not the TH1 inducing cytokines IL-12 and IL-18 is vital for EAE development 
initi ated a major paradigm shift  with regards to the role of TH1 cells in infl ammati on 
(78,79,99,153,154). The impact of IL-23 on TH cells appears to be restricted to memory 
cells, which in response to IL-23R engagement secrete IL-17 (153). IL-17 expression by T 
cells correlates superbly with an autoimmune pathogenic phenotype and this polarizati on 
patt ern was coined TH17 (101,169). While studying IL-23 under various infl ammatory 
conditi ons lead to the discovery of TH17 cells, it was later found that the cytokines TGF-β 
and IL-6 are dominant in their capacity to polarize TH17 cells (107,109). The role and 
functi on of IL-23 in maintaining this phenotype remains a subject of debate (153).
TH17 cells received much att enti on lately and mice lacking IL-17A were found to be 
moderately resistant to EAE (130). However, in contrast to IL-17A-/- mice, IL-23 defi cient 
mice are completely EAE-resistant (78,79). Thus, we reasoned that IL-17A is unlikely to be 
the only factor produced by TH17 cells involved in the infl ammatory process. To identi fy 
the expression signature of IL-23 driven genes, we used high density transcriptomics and 
identi fi ed IL-22 to be induced by IL-23 in autoimmune-pathogenic CD4+ T cells in a ti me- 
and dose-dependent manner. IL-22 belongs to the IL-10 super-family of cytokines and 
exhibits – unlike IL-10 – potent pro-infl ammatory properti es. Its recently reported role 
in psoriasis (140,145,146) combined with our fi nding that IL-22 is specifi cally induced by 
IL-23 points towards a relevant functi on of IL-22 in autoimmune infl ammatory diseases. 
Bett elli and colleagues further reported that IL-22 marks a parti cularly pathogenic 
populati on of autoreacti ve T cells implicati ng IL-22 as a major pathogenic cytokine during 
CNS infl ammati on (170). In additi on the IL-22 gene, together with IL-26 and IFN-γ on the 
human chromosome 12q14, are considered a prominent suscepti bility locus for MS (171). 
We found that following IL-23 sti mulati on, IL-22 is specifi cally secreted by pathogenic 
TH cells. To determine the actual role of this cytokine in autoimmune infl ammati on, we 
generated IL-22-/- mice, which were found to be surprisingly fully suscepti ble to EAE. We 
show that self-reacti ve TH cells coexpress IL-17 and IL-22, but that the latt er does not 
appear to be directly involved in autoimmune pathogenesis of the CNS.
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Results 
IL-23 induces IL-22 gene expression
To elucidate the identi ty of IL-23-driven gene transcripts, we devised two reciprocal 
approaches for whole genome transcriptomics. We compared gene-expression induced 
by IL-23 sti mulati on with those absent in Ag-driven IL-23 defi cient (p40-/-) lymphocytes. 
In the fi rst approach, genes upregulated (more than fourfold) by IL-23 were identi fi ed 
by sti mulati ng splenocytes obtained from an unmanipulated mouse with recombinant 
IL-23 or IL-12 as a control. In the second approach, we immunized wt, IL-12p35-/- and IL-
12/23p40-/- mice with keyhole limpet hemocyanin (KLH) and 7 dpi harvested lymphocytes 
and re-challenged them in vitro with KLH prior to harvesti ng the mRNA for microchip 
analysis (Aﬃ  metrix chip #MOE430A). We used IL-12 as a control fi rstly, because IL-12-
Figure 7: IL-22 
expression is 
specifi cally in-
duced by IL-23. 
(A) 4x106 sple-
nocytes were 
obtained from 
C57BL/6 mice, 
sti mulated with 20 
ng/ml of the indi-
cated substances 
and incubated for 
24 h. The superna-
tant was collected 
and used for IL-22 
and IL-17A protein 
detecti on by ELI-
SA. (B) 4x106 na-
ïve wt splenocytes 
were sti mulated 
with 20 ng/ml IL-
23 and collected at 
indicated ti me points or sti mulated with indicated concentrati ons of IL-23 and harvested aft er 
24 h. RNA was extracted, and quanti tati ve RT-PCR for IL-22 mRNA expression performed.  (C) 
4x106 CD8+ or CD4+ T cells were purifi ed from OT-I or OT-II splenocytes, respecti vely and incubated 
with cognate pepti de pulsed or unpulsed bone-marrow derived DCs for 48 h  and harvested aft er 
24 h. RNA was extracted, and quanti tati ve RT-PCR for IL-22-, IL-17- and IFN-γ mRNA expression 
performed. All data shown are representati ve of at least three individual experiments and SD 
were calculated from duplicate wells. (D) Splenocytes from a MOG-immunized C57BL/6 mouse 
were acti vated in vitro 7 dpi with 15 μg/ml MOG pepti de, 10 ng/ml IL-23, 20 ng/ml IL-6, 5 ng/ml 
hTGF-β, IL-7 and IL-2 and 5 μg/ml anti  IFN-γ ab to generate TH17 cells. Intracellular cytokine stain-
ing was performed on day 5. The plot is gated on CD45+CD4+ cells. Shown are the percentages 
only of polarized T cells. (E) Splenocytes were obtained from C57BL/6 mice and MACS-sorted for 
CD4+CD62Lhi and CD4+CD62Llo. 4x106 cells were sti mulated with 20 ng/ml IL-23 and harvested af-
ter 24 h. RNA was extracted, and quanti tati ve RT-PCR for IL-22 mRNA expression performed. Data 
shown are representati ve of three experiments.
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induced gene expression is well 
characterized and secondly to 
eliminate IL-12-induced target genes 
from our analysis. By combining 
both data sets, we found IL-22 to be 
specifi cally and strongly induced by 
IL-23 (data not shown).
To verify that IL-22 expression is 
specifi cally induced by IL-23, we 
treated splenocytes derived from 
unmanipulated C57BL/6 mice with an 
array of diﬀ erent sti muli, harvested 
the mRNA and measured IL-22 and 
IL-17A protein expression by ELISA 
(Fig. 7 A). Other than IL-23, none of 
the used substances elicited signifi cant levels of IL-22 and IL-17 expression in splenocytes 
aft er 24 h of sti mulati on. Diﬀ erent concentrati ons of the diﬀ erent sti muli were used (data 
not shown). Our data show that a populati on of splenocytes present in naïve pathogen-
free C57BL/6 mice respond to IL-23R engagement with IL-22 and IL-17 expression. To 
further characterize the kineti cs and dose-dependence of IL-23-induced IL-22 producti on, 
we sti mulated wt lymphocytes obtained from an untreated mouse with IL-23 for diﬀ erent 
periods of ti me or in the presence of diﬀ erent concentrati ons of IL-23 and observed that 
IL-22 expression is induced in a ti me- and dose-dependent manner (Fig. 7 B). We observed 
a similar expression patt ern with IL-17 (data not shown). To verify the noti on that TH cells 
and not CTLs are the main source of IL-22, we sti mulated purifi ed CD4+ as well as CD8+ 
T cells obtained from Ovalbumin TcR Tg mice (OT-II and OT-I respecti vely) with cognate 
pepti de pulsed DCs for 24 h and found that only TcR Tg CD4+ T cells made IL-22 (Fig. 7 C). 
By intracellular cytokine staining of TH17 cells, we could show that more than 90% of IL-22-
secreti ng cells also produce IL17, while fewer IFN-γ secreti ng cells coexpress IL-22 (20%) 
(Fig. 7 D). To identi fy whether IL-23 sti mulates the secreti on of IL-22 by naïve or memory 
T cells, we purifi ed memory T cells (CD62Llo) and naïve T cells (CD62Lhi) followed by an 
O/N sti mulati on with IL-23. Our data confi rm that IL-23 primarily drives the memory T 
cell pool and does not infl uence the naïve pool in regards to cytokine secreti on measured 
(Fig. 7 E).
Figure 8: IL-22 and IL-17 are produced by MOG-
reacti ve T cells upon encounter with their cog-
nate Ag. 
T cells from mice transgenic for the 2D2 T cell recep-
tor were isolated and sti mulated with MOG35-55 or 
control pepti de (5 μg/ml) pulsed mature bone-mar-
row derived DCs obtained from wt-, p35-/-- or p40-/-- 
mice for 2d and IL-22 and IL-17A protein expression 
was measured by ELISA. Shown is a representati ve 
of three individual experiments (n=4). 
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IL-22 is expressed by encephalitogenic TH cells
To determine the inducti on of IL-22 and IL-17A expression in a more physiologic manner in 
response to cognate Ag, we isolated T cells from MOG-reacti ve TcR transgenic (2D2) mice 
and sti mulated them with MOG35-55 or control pepti de-pulsed mature bone-marrow derived 
DCs obtained from wt-, IL-12p35-/-- or IL-12/23p40-/-- mice. IL-22 and IL-17A expression 
was subsequently measured by ELISA. MOG-reacti ve T cells clearly expressed high levels 
of IL-22 and IL-17A aft er encounter with their cognate anti gen (Fig. 8). This response is 
dependent on IL-23 as reduced levels of IL-22 and IL-17 were detectable when T cells 
were co-cultured with DCs obtained from p40IL-12/23-/- mice. We have also performed 
this resti mulati on experiment using polyclonal eﬀ ector T cells isolated from MOG-
immunized wt mice and confi rmed that the expression of IL-22 and IL-17 is dependent on 
the secreti on of IL-23 by APCs (data not shown). In order to analyze the expression of IL-
Figure 9: CNS infi ltrati ng TH17 cells express IL-22. 
Wt mice were immunized with MOG35-55 emulsifi ed in CFA and sacrifi ced either (A/C) at the peak 
of disease (d 21) or (B) at indicated ti me points aft er immunizati on. Lymphocytes were isolated 
out of CNS and spleen or LN of naïve or MOG35-55 immunized wt mice, resti mulated with 50 μg/
ml of their cognate anti gen MOG35-55 and IL-22-, IL-17A- and IFN-γ expression was analyzed by A) 
ELISA or (C) intracellular cytokine staining.  (A) Shown is a representati ve ELISA of four individual 
experiments (n=2/group/experiment). (B) Pre-onset disease was performed with n=3. (C) Shown 
are the percentages only of polarized T cells. Shown is a representati ve of 3 individual experi-
ments n=3.
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22 in mice with autoimmune infl ammati on, we induced EAE in wt C57BL/6 mice through 
immunizati on with MOG35-55 emulsifi ed in CFA and harvested brain and spinal cord as well 
as splenocytes at the peak of disease (d 21). Lymphocytes were isolated as described, 
challenged with MOG35-55 and analyzed for cytokine-expression aft er 48 h by ELISA (Fig. 
9 A). As expected, we found IFN-γ and IL-17 to be expressed by splenocytes and CNS-
invading lymphocytes. Most importantly, we detected a signifi cant producti on of IL-22 
by encephalitogenic, CNS-infi ltrati ng lymphocytes aft er re-encounter with their cognate 
MOG-anti gen in vitro. Kineti c analysis of IL-22 secreti on was performed by sacrifi cing mice 
at diﬀ erent ti me points aft er immunizati on with MOG/CFA. Similar to IFN-γ and IL-17, IL-
22 expression by CNS-infi ltrati ng lymphocytes increased with disease severity (Fig. 9 B). 
To study which populati on of polarized TH cells secrete IL-22 in peripheral organs and the 
infl amed CNS, we immunized C57BL/6 mice with MOG/CFA and harvested spleen, LNs 
and CNS at the peak of clinical EAE (average score of 3). The mononuclear cells were then 
resti mulated with MOG35-55 followed by intracellular cytokine staining. Cytofl uorometric 
analysis revealed that in spleen and LN, there is a high overlap of IL-17 and IL-22 secreti ng 
T cells, while in the infl amed CNS, IL-17 secreti ng cells dominate over IL-22 and IL-17/22 
secreti ng T cells (Fig. 9 C).
Tables II-IV: Distributi on of cell types of 
the immune system in C57BL/6 and IL-
22-/- mice. 
Spleens, LNs and thymi were obtained from 
unmanipulated C57BL/6 and IL-22-/- mice, 
cells were isolated and stained with fl ouro-
chrome conjugated abs against the indicat-
ed cell-type specifi c surface markers. Data 
shown are representati ve of three individual 
experiments.
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Gene targeting of IL-22 does not prevent EAE development
Given the clear expression patt ern of IL-22 associated with pathogenic TH17 cells, we 
sought to investi gate whether IL-22 plays a role in infl ammati on of the CNS. To do so, we 
generated IL-22-/- mice by replacing the coding-exons 1a, 1b, 2 and a part of exon 3 of the 
IL-22 gene with a neomycine resistant gene (Fig. 10 A) and verifi ed the absence of IL-22 by 
genomic PCR, RT-PCR and ELISA (Fig. 10 A, B and data not shown). The mice do not display 
any obvious malformati on of the hematopoieti c system and developed normally (Tables 
II-IV). When we analyzed the proliferati ng capacity as well as the cytokine expression 
profi le of IL-22-/- cells aft er re-encounter with MOG35-55 by thymidin incorporati on or ELISA, 
respecti vely, we observed that they behaved similar to wt cells (Fig. 10 C, D). 
We induced EAE in the IL-22-/- mice through immunizati on with MOG/CFA and recorded 
the clinical disease development. In spite of our expectati ons that IL-22 would display 
Table V: IL-22-/- are fully suscepti ble to EAE.
IL-22+/+ and IL-22-/- mice were immunized with 
MOG35-55 emulsifi ed in CFA and the clinical score re-
corded as described. Three merged representati ve 
experiment (n≥19) of fi ve individual experiments 
are shown. Onset and max. clinical score is calculat-
ed ± Average deviati on. Stati sti cal signifi cance was 
determined using an unpaired Student’s T-test.
Figure 10: Generati on and character-
izati on of IL-22-/- mice. 
(A) The structure of the IL-22a locus, the 
targeti ng vector, and the predicted ho-
mologous recombinati on are shown. The 
exons are shown as boxes, with white 
and black boxes for non coding and cod-
ing regions respecti vely. The size of the 
5’and 3’ arms, as well as the locati on of 
the primers used for genotyping are in-
dicated. Neo, neomycin resistance cas-
sett e, TK, thymidine kinase cassett e. For 
genotyping, the wt and targeted alleles 
were amplifi ed from F2 tail genomic DNA 
as described in material and methods. 
Lymphocytes were isolated out of spleen 
of MOG35-55 immunized wt or IL-22
-/- mice, 
resti mulated with 50 μg/ml of their cog-
nate anti gen MOG35-55 or 5 μg/ml ConA. 
(B) IL-22 expression was analyzed by ELI-
SA, (C) proliferati on was measured by thy-
midin uptake (shown is a representati ve 
of 3 individual experiments n=3) or (D) IL-
17A and IFN-γ expression was analyzed by 
ELISA. Data shown are representati ve of 
at least three individual experiments and 
SD were calculated from duplicate wells. 
A
B C
D
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pro-infl ammatory encephalitogenic properti es, we observed that IL-22-/- mice developed 
disease similar to wt controls (Fig. 11 A & Table V). Cytofl uorometric analysis of CNS 
invading mononucleated cells revealed that their numbers and subset-distributi ons are 
indisti nguishable between the infl amed CNS of wt and IL-22-/- mice (Fig. 11 B). Histological 
analysis of spinal cord cross-secti ons further displayed similar infl ammatory lesions 
consisti ng of acti vated Iba1+ macrophages/microglia, CD3+  T cells and few B220+ B-cells 
resulti ng in an impairment of myelinated and axonal structures (Fig. 11 C and data not 
shown). Therefore, while IL-22 is clearly expressed by encephalitogenic TH17 cells, it does 
not appear to be crucial for the development of autoimmune infl ammati on of the CNS. 
Figure 11: IL-22-/- mice are fully suscepti ble to EAE. 
(A) IL-22+/+ and IL-22-/- mice were immunized with MOG35-55 emulsifi ed in CFA and the clinical score 
recorded as described. Two merged representati ve experiment (n≥12) of fi ve individual experi-
ments are shown. Error bars represent the average deviati on. (B) Mice were sacrifi ced at the peak 
of disease (d 22), lymphocytes were isolated out of CNS, stained for the indicated surface markers 
and analyzed by fl ow cytometry. The histogram represents a staining for CD45 to disti nguish CNS 
resident microglia (CD45lo) from CNS-invading leukocytes (CD45hi). Shown is an average of 5 indi-
vidually analyzed mice ± Average deviati on. (C) Spinal cord cross-secti ons of wt and IL-22-/- mice 
displayed similar infl ammatory lesions (arrows), which oft en appeared to be accentuated around 
vessels. They consisted of many acti vated Iba1+ macrophages/microglia (2nd and, at higher magni-
fi cati on, 3rd row) and caused an impairment of myelinated and axonal structures, as depicted by a 
Luxol-Nissl (LN, 4th row) as well as a neurofi lament (NF) stain (5th row). Scale bars: 100 μm for 1st, 
3rd, 4th and 5th column, 100 μm for 2nd, 4th and 6th column. 
A
B
C
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Discussion
In the recent past, the functi on, origin and regulati on of IL-17 expressing TH cells received 
much att enti on by the immunology community. The discovery of this TH polarizati on 
profi le (TH17) fi nally does resolve a number of confl icti ng fi ndings regarding the TH1/2 
paradigm of ti ssue directed autoimmune disease (153). The expression of IL-17 by TH cells 
correlates extremely well with their pathogenicity during autoimmunity.
However, in spite of this close correlati on (99,101,169), several questi ons regarding their 
actual eﬀ ector functi on remain unanswered. Foremost, the fact that IL-23 is absolutely 
vital for the development of autoimmune disease, whereas IL-17A alone has only a 
moderate impact (130), raises the questi on whether additi onal thus far unidenti fi ed IL-
23-driven cytokines have pathogenic properti es. We sought to resolve this questi on by 
the global analysis of IL-23-induced genes in lymphocytes. We discovered IL-22 to be the 
most prominent gene expressed by TH cells aft er IL-23 treatment. We further found that 
self-reacti ve TH cells required the presence of IL-23 for IL-22 producti on and that IL-23-
defi cient APCs were not able to properly induce IL-22 by sti mulati on of a populati on of 
MOG-reacti ve T cells. In agreement with Liang et al., we found IL-22 to be highly expressed 
by TH17 cells (139). This suggested that IL-22 could potenti ally serve a pathogenic functi on 
during EAE. To this end, we performed a longitudinal analysis of IL-22 expression during 
EAE and found a strong correlati on between T cell pathogenicity and IL-22 secreti on. 
Bett elli et al. (170) recently claimed that IL-22 expression ‘marks’ a highly pathogenic and 
proinfl ammatory populati on of autoaggressive T cells, heavily implicati ng IL-22 to exert 
a pathogenic functi on during EAE. Also, the receptor for IL-22, a heterodimer of the IL-
10R2 and IL-22R1, like the IL-17A receptor is found primarily on stroma- cells including 
endothelial cells, epithelials cells and CNS-resident astrocytes (146,170,172). The close 
associati on of IL-22 and IL-17 in pathogenic TH cells, their inducibility by IL-23 and the fact 
that their receptors are expressed by similar cell types, implies that IL-22 too serves a pro-
infl ammatory pathogenic role in CNS infl ammatory disease.
In order to determine whether IL-22 actually contributes to the development of EAE or 
whether the crisp correlati on between IL-22 expression and encephalitogenicity is only 
an epiphenomenon, we generated IL-22-/- mice by gene-targeti ng. To our surprise, we 
discovered that IL-22-/- mice develop EAE with the same severity, day of onset and clinical 
manifestati ons as wt mice. This fi nding clearly dismisses IL-22 as a major pathogenic 
player in the development of autoimmune CNS infl ammati on. The functi on of IL-22 in 
autoimmunity however cannot be dismissed altogether. Wolk et al. reported that elevated 
levels of IL-22 can be found in the blood of psoriati c pati ents and ear-skin acanthosis 
and infl ammati on induced by the applicati on of IL-23 is slightly decreased when IL-22 is 
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absent (140,145).
Taken together, the noti on that a cytokine is considered to have pathogenic functi ons 
cannot be based on its mere presence in a potenti ally pathogenic populati on of T cells. 
This line of thought had lead to a biased interpretati on of the role and functi on of TH1 and 
TH2 cells in the context of autoimmune disease (153,173-175). We were able to identi fy 
such a pro-infl ammatory factor, namely IL-22, which is like IL-17A closely associated with 
an encephalitogenic phenotype. However, the fact that IL-22-/- mice develop severe EAE 
indicates that IL-22, just like IFN-γ, is not among the pro-infl ammatory factors mediati ng 
the ti ssue damage seen in EAE. The requirement of the transcripti ons factors which drive 
TH1 and TH17 polarizati on (T-bet and ROR-γt respecti vely) indicates that features, other 
than the main cytokines produced, are responsible to their pathogenic behavior. While 
TH17 cells secrete IL-17 as well as IL-22, the report by Kebir et al. (176) suggests that 
cytolyti c enzymes and factors that alter the integrity of the blood-brain-barrier may be 
responsible for the encephalitogenicity of human TH17/22 cells. It is however likely that 
amongst the genes expressed by TH17 cells, a number of them may turn out to serve as 
biomarkers if not therapeuti c targets in the treatment of autoimmune diseases in general 
and MS in parti cular. 
Materials and Methods
Peptides, Antibodies and recombinant cytokines
MOG35–55 pepti de (MEVGWYRSPFSRVVHLYRNGK) and OVA323–339 (ISQAVHAAHAEINEAGR) 
were obtained from Research Geneti cs (Huntsville, Alabama, USA). All recombinant 
cytokines were purchased from PeproTech and all anti bodies were purchased from BD 
Biosciences. The anti body to murine IL-22 was kindly provided by Genentech, Inc. and 
labeled with Alexa 488 (Invitrogen) according to the manufacturer’s directi ons.
Mice and induction of EAE
C57BL/6 mice, IL-12 p35-/-- and IL-12 p40-/- mice on a C57BL/6 background were purchased 
from The Jackson Laboratory (Bar Harbor, Maine) and were bred under specifi c pathogen-
free conditi ons. The 2D2 (MOG-TCR-Tg) mice were provided by V. Kuchroo (Harvard 
Medical School, Boston, Massachusett s). IL-22-/- mice were generated by targeti ng exons 
1-3 and backcrossed onto C57BL/6 for more than 8 ti mes. The targeti ng vector was 
constructed to replace the exons 1a, 1b, 2 and a part of exon 3 of the IL-22a gene by a 
neomycine resistant gene. A 5’arm of 1521 base pairs was amplifi ed using a mutated sense 
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primer with a Xho1 site 5’-CTTCGGCTCGAGATGGCCAC-3’ a mutated anti sense primer 
containing also a Xho1 site 5’-GCCCTCGAGACACCAGGGTT-3’ to allow the direct inserti on 
into the pPNT vector. The 3’arm consisted of a 3559 bp Kpn1 fragment, containing the 
end of exon 3 and exon 4 was cloned. For genotyping, the targeted gene was amplifi ed 
using a sense primer located upstream the 5’arm: 5’ CTGCTGTCCAACAGAGCTCT-3’ and 
anti sense primer on neomycine gene: 5’-CGCCTCCCCTACCCCGGTAGA-3’, resulti ng in a 1.7 
kb amplifi ed sequence. The wild type gene was amplifi ed using a sense primer located 
into the 5’arm 5’-AATCTATGAAGTTGGTGGGA-3’ and an anti sense primer located on exon 
2 5’-ACTGACTCCTCGGAACAGTT-3’, resulti ng in a 1.2 kb amplifi ed sequence. Mouse IL-22 
RT-PCR was performed as previously described (131). EAE was induced and scored as 
described (36). 
Histology and Flow cytometry
Whole mouse brains or spinal columns were fi xed in 4% paraformaldehyde in PBS, paraﬃ  n-
embedded, cut and stained with hematoxylin-eosin (H&E) and Luxol-Nissl (LN) according 
to standard protocols. Immunohistochemical stainings on serial secti ons using anti bodies 
to neurofi lament protein (NF, 200 kD subunit, 1:20, Bio-Science), Iba1 (1:100, Wako 
Chemicals), CD3 (1:150, Labvision) and B220 (1:1000, Becton Dickinson) were carried 
out on an automated Nexus staining apparatus (Ventana Medical Systems), following 
the manufacturer’s guidelines. CNS infi ltrati ng lymphocytes were isolated as described 
previously (154). For fl ow cytometry, anti bodies were incubated with cells for 20 min 
at 4 °C and then cells were analyzed with a FACSCalibur (BD Pharmingen) and FACSDiva 
soft ware. Post-acquisiti on analysis was done with FACSDiva (BD Pharmingen) or FlowJo7 
soft ware (Tree Star, Inc.) For intracellular cytokine staining, cells were resti mulated with 
50 ng/ml PMA, 500 ng/ml ionomycin and GolgiPlug (BD Biosciences) for 5 h. Cells were 
fi rst stained for surface anti gens and then permeabilized with Cytofi x/Cytoperm (BD 
Biosciences) according to the manufacturer’s recommendati ons. Intracellular cytokine 
staining was performed using anti bodies to IFN-γ, IL-17A or IL-22 as described above. 
Cell culture and in vitro assays
Mice were sacrifi ced using CO2, axillary and inguinal lymph nodes (LN) and spleens 
were collected and treated with 0.5mg/mlDNase and 1mg/ml Liberase (Roche) for 30 
min at 37°. Cells were cultured in RPMI supplemented with 10% FCS, 50 U/ml penicillin 
and 50 μg/ml streptomycin (Gibco) in the presence or absence of the factors indicated 
in the fi gure legends and harvested at indicated time points. Where indicated, T cells 
were purifi ed from splenocytes by magneti c cell sorti ng with MACS® Beads following the 
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manufacturer’s recommendati on (Miltenyi Biotec). BM-derived DCs were generated as 
described (154). To mature DCs, 10μg/ml LPS (Fluka) was added to the culture for 24h. 
Mature DCs were pulsed with 5 μg/ml pepti de for 4 h, washed extensively and incubated 
with splenocytes at a rati o of 1:4 and harvested aft er 48 h. 
Cytokine analyis
Elisa for IL-17A (BD Pharmingen, La Jolla) and IL-22 (Anti genix, Hunti ngton Stati on, NY) 
were preformed according to the manufacturer’s instructi ons. Proliferati on of MOG-
reacti ve cells were sti mulated in triplicate for 48 h with either 50 μg/ml of MOG35–55, 5 μg/
ml of concanavalin A, or medium and 0.5 μCi/ml of [3H]thymidine was added aft er 24 h 
for assessment of proliferati ve responses. Thymidine incorporati on was assessed with a 
Filtermate Collecter (Applied Biosystems) and a scinti llati on and luminescence counter.
Real-time RT-PCR
Cells or ti ssues were homogenized in 1 ml Trizol reagent (Invitrogen). Total RNA was 
extracted and reverse transcription performed using random hexamer primer and 
Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen). After PCR 
amplifi cation using SYBR Green PCR master mix (Invitrogen), quantitative values of each 
sample were normalized to its β-actin content and converted to relati ve cDNA quanti ti es 
by comparison to a standard curve generated with diluti ons of β-actin plasmid. Primers 
were purchased from Operon Technologies (Alameda CA). The primers used were 
(5’-3’) β-actin fw: AGAGGGAAATCGTGCGTGAC, β-actin rev: CAATAGTGATGACCTGGCCGT, 
IL-22 fw: TTGAGGTGTCCAACTTCCAGCA, IL-22 rev: AGCCGGACGTCTGTGTTGTTA, IL-17 fw: 
ATCAGGACGCGCAAACATGA, IL-17 rev: TTGGACACGCTGAGCTTTGA.
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Abstract
TH17 lymphocytes appear to be essenti al in the pathogenesis of numerous infl ammatory 
diseases. We demonstrate here the expression of IL-17 and IL-22 receptors on blood-
brain barrier endothelial cells (BBB-ECs) in multi ple sclerosis lesions and show that 
IL-17 and IL-22 disrupt BBB ti ght juncti ons in vitro and in vivo. Furthermore, TH17 
lymphocytes transmigrate eﬃ  ciently across BBB-ECs, highly express granzyme B, kill 
human neurons and promote central nervous system infl ammati on through CD4+ 
lymphocyte recruitment.
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Results and Discussion
T-helper type 1 (TH1) (177,178) and type 17 (TH17) lymphocytes contribute to autoimmune 
infl ammatory diseases(179) including multi ple sclerosis and its mouse model, 
experimental autoimmune encephalomyeliti s (EAE) (99,101). Disrupti on of the BBB and 
traﬃ  cking of autoreacti ve T cells from the systemic compartment into the central nervous 
system (CNS) are important, early events in the development of multi ple sclerosis lesions 
(180). In support of TH1 lymphocytes have been shown to migrate eﬃ  ciently across the 
human BBB (181,182). To evaluate TH17 lymphocyte migrati on to the brain relati ve to 
TH1 cells, we employed an in vitro model of the human BBB using human brain-derived 
microvascular endothelial cells. We generated human TH1 and TH17 lymphocytes in vitro 
using peripheral blood CD4+ lymphocytes cultured with IL-12 and IL-23, respecti vely. 
Human TH17 lymphocytes migrated more avidly across the BBB than did TH1 or freshly 
isolated (ex vivo) CD4+ lymphocytes (Fig. 12 A, P < 0.01). To ensure that the selecti ve 
accumulati on of TH17 lymphocytes indeed refl ects the preferenti al transmigrati on ability 
of TH17 cells, we analyzed the intracellular cytokine profi le of the cell populati on before 
and aft er migrati on across BBB-ECs, looking specifi cally at IL-17 and at IL-22, a recently 
identi fi ed cytokine product of TH17 cells (139,140,183). We noted a signifi cant enrichment 
in the number of IL-17– and IL-22–expressing CD4+CD45RO+ memory lymphocytes upon 
migrati on across the BBB (Fig. 12 B, P < 0.001 for IL-17+ and P < 0.05 for IL-22+ cells, n = 3), 
confi rming the ability of TH17 lymphocytes to cross the BBB in vitro. To further substanti ate 
these observati ons, we generated myelin oligodendrocyte glycoprotein (MOG)-specifi c 
TH1 and TH17 lymphocytes from 2D2 mice in vitro and transferred these separately into T 
and B lymphocyte–defi cient Rag1-/- mice. Equal numbers of TH cells were found in the CNS 
of Rag1-/- mice 7 d aft er transfer, regardless of whether donor cells were polarized into TH1 
or TH17 cells, confi rming that TH1 and TH17 cells primed and expanded in the periphery 
access the CNS in vivo (Fig. 12 C). To validate these human in vitro and mouse in vivo 
observati ons, brain secti ons from humans with multi ple sclerosis and from unaﬀ ected 
controls were immunostained for CD45RO and IL-17 or IL-22. Numerous CD45RO+ cells 
immunopositi ve for IL-17 or IL-22 were detected in highly infi ltrated multi ple sclerosis 
lesions, but not in normal-appearing white matt er or non-infl amed brain specimens 
(Fig. 12 D, E). Taken together, these results emphasize the potenti al importance of TH17 
lymphocyte infi ltrati on into the CNS and these lymphocytes’ consequent involvement in 
lesion formati on in multi ple sclerosis and EAE.
So far, the encephalitogenic acti vity of TH17 cells has been att ributed to IL-17 (130,184). To 
investi gate whether the acti on of TH17 cells extends beyond the proinfl ammatory infl uence 
of IL-17, we explored the possibility that TH17 cells might express cytolyti c molecules and 
Human TH17 cells promote BBB disrupti on
64
therefore analyzed TH17 cells for the expression of perforin, granzyme A and B. Notably, 
whereas virtually no ex vivo CD4+CD45RO+ cells produced cytolyti c enzymes (data not 
shown), granzyme B was expressed in as many as 22.5% of IL-17–producing CD4+CD45RO+ 
cells and 17.3% of IL-22+ lymphocytes aft er 6 d of culture with IL-23 (Fig. 12 F). Even more 
striking is that 60% of cells coexpressing IL-17 and IL-22 also expressed granzyme B (Fig. 
Figure 12: TH17 lymphocytes mi-
grate eﬃ  ciently across the BBB in 
vitro and in vivo and kill human 
neurons. 
(A) Human CD4+CD45RO+ TH17, CD4
+ TH1 
(both generated in vitro, see Supplemen-
tary Methods) and ex vivo CD4+ lympho-
cytes were allowed to migrate across 
human BBB-ECs in a modifi ed Boyden 
chamber assay for 18 h. Signifi cantly more TH17 lymphocytes migrated than either TH1 or ex vivo 
CD4+ lymphocytes. (B) CD4+CD45RO+ TH17 lymphocytes were allowed to migrate across human 
BBB-ECs for 18 h. Cells were stained for IL-17 and IL-22 before and aft er migrati on. The cytokine 
profi le revealed the preferenti al migrati on of IL-17+ and IL-22+ lymphocytes. (C) Immune cells from 
lymph nodes and spleen of MOG35–55-immunized 2D2 mice were polarized toward TH1 or TH17 and 
transferred to Rag1-/- mice, and CD45hiCD4+ lymphocytes were isolated from the CNS 7 d aft er 
transfer. Shown is a representati ve fl ow cytometry dot plot of CNS cell content from Rag1-/- mice 
injected with either TH1- (left ) or TH17-polarized (right) 2D2 lymphocytes (n = 4 mice per group). 
(D) Human CNS postmortem material from unaﬀ ected individuals (control, non-infl amed, above) 
and heavily infi ltrated CNS material from individuals with multi ple sclerosis (below) were immu-
nostained for CD45RO (red), IL-17 (green) and nuclear stain TO-PRO3 (blue). Confocal microscopy 
imaging confi rmed the presence of IL-17+CD45RO+ cells (yellow) in infi ltrated multi ple sclerosis 
lesions but not in control CNS. Bar, 75 μm. (E) Similarly, IL-22+CD45RO+ staining was observed in 
multi ple sclerosis lesions, but not in control CNS material. (F) Human CD4+CD45RO+ TH17–polar-
ized lymphocytes were stained for CD45RO, IL-17, IL-22 and granzyme B. Both IL-17– and IL-22
–producing lymphocytes expressed granzyme B (22.5% and 17.3%, respecti vely). (G) More than 
60% of IL-17+IL-22+ lymphocytes highly expressed granzyme B. Granzyme A and perforin were not 
detected in TH17 cells, whether or not these cells produced IL-22 (data not shown). (H) The cy-
totoxic acti vity of TH17 lymphocytes was assessed using neuron-enriched cultures obtained from 
human fetal CNS material and compared to that of unacti vated T lymphocytes. All data shown are 
representati ve of the mean s.e.m. of three independent experiments.
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12 G). We therefore tested the capacity of granzyme B+ TH17 cells to kill human fetal 
neuron–enriched cultures and found that they showed considerable cytolyti c acti vity 
(32.83 2.54%) as compared to unacti vated T lymphocytes (6.15 2.37%) (Fig. 12 H, P < 
0.0001, n = 3).
We next analyzed IL-17 receptor (IL-17R) and IL-22 receptor (IL-22R) expression on human 
BBB-ECs and investi gated whether IL-17 and IL-22 infl uence BBB integrity. IL-17R and IL-22R 
were detected on the surface of a subset of human BBB-ECs in primary culture (Fig. 13 A, 
23% of IL-17R+ and 16% of IL-22R+). In situ, however, IL-17R and IL-22R were undetectable 
in CNS material from subjects without multi ple sclerosis. However, both receptors were 
strongly expressed on CNS vessels within heavily infi ltrated multi ple sclerosis lesions, 
colocalized with caveolin-1, a marker of brain endothelial cells (Fig. 13 B, C).
We further investi gated whether brain endothelial IL-17R and IL-22R were functi onal and 
whether IL-17 and IL-22 could aﬀ ect BBB permeability. Additi on of 10 ng/ml of IL-17 or 
IL-22 to monolayers of human BBB-ECs induced a marked and sustained increase in the 
diﬀ usion of fl uorescence-labeled BSA (Fig. 13 D). This eﬀ ect was dose dependent, reached 
a plateau at 100 ng/ml and coincided, for IL-17, with a decrease in the expression of 
occludin and zonula occludens (ZO)-1, two important ti ght juncti on–associated molecules 
(Fig. 13 E). A similar reducti on of occludin and to a lesser extent ZO-1, expression was 
demonstrated by western blotti  ng in spinal cord homogenates from EAE mice (Fig. 13 
F). In situ staining further confi rmed a decrease in ZO-1 immunoreacti vity in cerebellar 
lesions of MOG-immunized mice (Fig. 13 F) These results are in line with our recent data 
showing a disrupti on of ti ght-juncti on proteins in highly infi ltrated vessels of multi ple 
sclerosis lesions (185). The exact mechanism mediati ng IL-22–induced BBB permeability 
remains uncertain, however.
We next explored the capacity of IL-17 and IL-22 to modulate lymphocyte migrati on across 
human BBB-ECs and found that IL-17 and IL-22 promote transmigrati on of human ex vivo 
CD4+ lymphocytes (Fig. 13 G), most likely through enhanced BBB-EC–mediated secreti on of 
CCL2 (or MCP-1) (Fig. 13 H). IL-17 also induced IL-6 and CXCL8 (or IL-8) expression by BBB-
ECs, whereas expression of TGF-β, ICAM-1, VCAM-1, CCL5 (or RANTES) and CXCL10 (or IP-
10) remained unaﬀ ected (data not shown). Taken together, these results strongly suggest 
that TH17 cells, through the acti on of IL-17 and IL-22, play a unique role in permeabilizing 
the human BBB both to soluble molecules and to circulati ng CD4+ lymphocytes.
Our study further refi nes the phenotype of human TH17 lymphocytes as cells coexpressing 
IL-17, IL-22 and granzyme B and provides strong evidence that IL-17 and IL-22 induce a 
breach in the BBB and promote the recruitment of additi onal CD4+ lymphocytes. Although 
IL-22 has the potenti al to infl uence the ability of TH17 lymphocytes to gain access to the 
CNS, in vivo evidence indicates that IL-22 does not directly aﬀ ect their encephalitogenicity 
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(B.B., personal communicati on). We postulate that TH17 cells produce multi ple mediators 
contributi ng to their highly encephalitogenic potenti al, among them cytolyti c enzymes 
such as granzyme B.
Figure 13: IL-17 and IL-22 receptors are expressed on human brain endothelium, and 
their acti vati on permeabilizes the BBB. 
(A) Unacti vated human BBB-ECs grown in primary culture were stained for IL-17R and IL-22R, 
revealing their expression on the surface of 23.2% and 16.6% of BBB-ECs, respecti vely. (B) Human 
CNS postmortem material from unaﬀ ected individuals (control, non-infl amed, above) and heavily 
infi ltrated CNS material from individuals with multi ple sclerosis (below) were immunostained for 
IL-17R (green), caveolin-1 (red) and nuclear stain TO-PRO3 (blue). Confocal microscopy imaging 
confi rmed the expression of IL-17R on caveolin-1+ endothelium in infl amed CNS material. IL-17R 
expression was undetectable in control CNS material. Bar, 75 μm. (C) Similarly, IL-22R staining was 
observed on endothelial cells in multi ple sclerosis lesions, but not in controls. (D) Human BBB-ECs 
were grown in Boyden chambers and treated with IL-17 (top) or IL-22 (bott om). Permeability of 
the monolayers was monitored with fl uorescent BSA, showing that BBB-EC monolayer perme-
ability increased aft er treatment with either IL-17 or IL-22. (E) Western blot for the ti ght-juncti on 
proteins occludin, ZO-1 and juncti on adhesion molecule (JAM)-1 from human BBB-ECs revealed 
disrupti on of occludin and ZO-1 by IL-17 (100 ng/ml, 18 h). (F) Western blot for ti ght-juncti on pro-
teins in spinal cord homogenates of MOG35–55-immunized EAE mice revealed a similar reducti on 
in occludin and ZO-1. In situ immunostaining for ZO-1 (red) and nuclear stain TO-PRO3 (blue) in 
normal-appearing cerebellar white matt er (control) and in infi ltrated and demyelinated cerebellar 
lesions from C57BL/6 mice immunized with MOG35–55 (EAE, grade 4). Confocal microscopy imaging 
confi rmed disrupti on of ZO-1 around infi ltrated vessels. Bar, 75 μm. (G) Freshly isolated peripheral 
blood human CD4+ lymphocytes were allowed to migrate for 18 h across IL-17– (100 ng/ml) or 
IL-22–treated (100 ng/ml) human BBB-ECs. Both cytokines promoted migrati on of human ex vivo 
CD4+ lymphocytes across human BBB-ECs, as compared to control. (H) CCL2 (or MCP-1) secreti on 
by human BBB-ECs was assessed by ELISA in untreated and IL-17– or IL-22–treated cultures (100 
ng/ml, 18 h). Both IL-17 and IL-22 upregulate CCL2 secreti on by human BBB-ECs. All data shown 
represent the mean s.e.m. from three independent experiments performed in triplicate.
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Materials and Methods
In vitro TH polarization 
We isolated mononuclear cells from peripheral blood of healthy human donors by density 
gradient centrifugati on on Ficoll-Hypaque (GE Healthcare). We purifi ed human CD14+ 
monocytes, CD4+ T lymphocytes and memory (CD4+CD45RO+) T lymphocytes by magneti c 
sorti ng (Miltenyi Biotec) according to the manufacturer’s instructi ons. The cell purity 
was consistently >97%, as determined by fl ow cytometry. T cells (1 × 106 cells/ml) were 
cultured with autologous monocytes as anti gen-presenti ng cells, at a two to one rati o 
and sti mulated with CD3-specifi c anti body (2.5 μg/ml, clone OKT3, eBioscience) in RPMI 
1640 medium supplemented with 5% human serum, 2 mM L-glutamine and anti bioti cs 
(Sigma). For TH1 polarizati on, we added recombinant human IL-12 (10 ng/ml) and anti body 
to human IL-4 (5 μg/ml, clone 3007), whereas for TH17 polarizati on, T cells were cultured 
in the presence of recombinant human IL-23 (10 ng/ml) as well as with neutralizing 
anti bodies against IFN-γ (5 μg/ml, clone K3.53) and against IL-4. Recombinant cytokines 
and anti bodies were purchased from R&D Systems. We harvested cells on d 6 for cytokine 
determinati on using commercially available ELISA kits for IFN-γ (BD Biosciences), IL-17 
(Biosource) and IL-22 (R&D Systems) following the manufacturer’s instructi ons. Levels of 
IL-17 and IL-22 were consistently higher in IL-23-sti mulated lymphocytes, as compared to 
TH1 and ex vivo lymphocytes (data not shown).
Intracellular cytokine staining and flow cytometry
Aft er 6 d in culture under TH1- or TH17-biased conditi ons, we sti mulated the cells 6 h with 
phorbol 12-myristate 13-acetate (20 ng/ml) and Ionomycin (1 μg/ml) in the presence of 
brefeldin A (2 μg/ml) (all from Sigma). We fi rst stained cells for surface anti gens CD3 and 
CD45RO then fi xed and permeabilized them in 4% (w/v) paraformaldehyde containing 
1% saponin. Subsequently, we added anti bodies specifi c for human IL-17 (Biosource), 
IL-22 (R&D Systems), perforin, granzyme A (BD Biosciences) and granzyme B (Caltag 
Laboratories). IL-17R and IL-22R expression on BBB-ECs was detected using unconjugated 
anti bodies (R&D
Systems) incubated with phycoerythrin-conjugated goat anti body specifi c to 
immunoglobulins (BD Biosciences). All staining assays were performed with the 
appropriate matched isotype control. Samples were acquired on a BD Biosciences LSR II 
fl ow cytometer and analyzed using BD FACSDiva Soft ware. 
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BBB-EC isolation & culture. 
We isolated BBB-ECs from CNS ti ssue specimens of temporal lobe resecti ons from 
young adults undergoing surgery for the treatment of intractable epilepsy, as previously 
described (181,186). Informed consent and ethic approval were given prior to surgery 
(Comité d’Evaluati on de la Recherche du CHUM, ethic approval number HD04.046). 
Cultures express endothelial markers factor VIII, Ulex Agglutenens Europaensis-1 binding 
sites and anti gen HT-7 unti l passage seven to eight. No immune reacti vity with β-tubulin, 
α-myosin or glial fi brillary acidic protein (GFAP) could be detected, confi rming the absence 
of contaminati ng smooth muscle cells or astrocytes.
Migration assays. 
Migrati on assays were performed on a 24-well plate modifi ed Boyden chamber as 
previously described (181,182). In brief, we seeded 3 × 104 human brain ECs on top of 
a gelati n-coated 3 μm pore size membrane in EC culture media supplemented with 40% 
(v/v) astrocyte-conditi oned media, shown to induce and maintain BBB characteristi cs 
in vitro. Aft er 3 d of culture, the ECs had formed a confl uent monolayer. At that point, 
when applicable, cells were treated for 24 h with 100 ng/ml of recombinant human IL-
17 or IL-22 (R&D Systems). The next day, ECs were washed and a suspension of 1 × 106 T 
lymphocytes/ml was loaded in the upper chamber. We assessed the ability of both TH1 and 
TH17 lymphocyte subsets to cross the monolayer by counti ng the absolute number of cells 
that transmigrated to the lower chamber aft er 18 h, out of the 1 × 106 cells initi ally loaded 
in the upper chamber. All migrati on data shown represent at least three independent 
experiments performed in triplicate.
Permeability assays. 
We performed the permeability assays on the in vitro model of the human BBB, as 
described for the migrati on experiments. We treated BBB-ECs on d 3 with 10 ng/ml or 
100 ng/ml of recombinant human IL-17 or IL-22. Aft er 24 h, we replaced the media and 
applied 50 μg/ml of fl uorescein isothiocyanate-labeled BSA (Invitrogen) to the upper 
chamber. Fift y μl samples
were taken from the upper and lower chambers at diﬀ erent ti me points over a 3 d period 
and the fl uorescence intensity in these samples was measured using a FL600 microplate 
fl uorescent reader (Biotek). The diﬀ usion rate, a measure of the permeability of BBB-ECs, 
was expressed as a percentage and calculated as follows: [BSA lower chamber] × 100 / 
[BSA upper chamber]. Each experiment was repeated at least three ti mes in triplicate to 
ensure reproducibility.
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Immunohistofl uorescence staining for IL-17, IL-22, IL-17R and IL-22R.
Frozen CNS material from healthy donors (non-neurological disease controls) and MS 
subjects was obtained aft er autopsy. Ten μm secti ons were cut, fi xed for 20 min in 4% 
paraformaldehyde and permeabilized with 1% triton X-100 for 5 min. Secti ons were 
blocked in HHG (1 mM HEPES, 2% horse serum, 10% goat serum in HBSS, Sigma) plus 0.5% 
triton X-100 for 1 h at room temperature, followed by overnight incubati on at 4 °C with 
mouse anti bodies specifi c to human IL-17 (1/20, eBiosciences) or human IL-22 (1/20, R&D 
Systems) and allophycocyanin-conjugated mouse anti body specifi c to human CD45RO 
(1/10, BD Biosciences). For the receptors, we used goat primary anti bodies against human 
IL-17R and human IL-22R (1/20, R&D Systems) and rabbit anti body specifi c to human 
caveolin-1 (1/50, Santa Cruz). Aft er several washes, IL-17, IL-22, IL-17R and IL-22R stains 
were amplifi ed with bioti n-conjugated goat anti body specifi c to mouse immunoglobulins 
(1/300) followed by streptavidin-fl uorescein isothiocyanate (1/300 for IL-17 and IL-22, 
1/1,000 for IL-17R and IL-22R, for 30 min at room temperature). CD45RO staining was 
visualized with allophycocyanin-specifi c anti body raised in rabbit (10 μg/ml, Biomeda) 
followed by Cy3-coupled goat anti body specifi c to rabbit immunoglobulins (1/300, Jackson 
ImmunoResearch). Caveolin-1 staining was visualized with Cy3-coupled goat anti body 
specifi c to rabbit immunoglobulins (1/400). Nuclei were stained with TOPRO3 (1/300 in 
phosphate buﬀ ered saline for 15 min, pre-treatment with 100 μg/ml RNase A for 30 min, 
Molecular Probes). All control staining were performed omitti  ng the primary anti body, 
in which case no immunopositi ve cells could be detected. Staining was visualized using a 
Leica SP5 confocal microscope and analyzed with Leica LAS AF Soft ware.
Cytotoxicity assays of fetal human neuron-enriched cultures
Brain ti ssue from human fetuses of 16–20 weeks gestati onal age were obtained following 
therapeuti c aborti on according to guidelines approved by the Research and Ethic 
Committ ee, University of Alberta and informed consent was given by the parents. Neuron-
enriched cultures (>90% purity) were prepared as previously described (187) and 1 × 105 
cells were plated in individual chambers 72 h prior to the killing assay. 1 × 105 unacti vated 
lymphocytes and IL-23-sti mulated TH17 cells were added to the neurons for 24 h, fi xed with 
4% paraformaldehyde and labeled with a monoclonal anti body to microtubule-associated 
protein (MAP)-2 (1/1,000, Sigma). Neuron (MAP-2+ cells) survival was evaluated counti ng 
six random fi elds in each well using the 40 × microscope objecti ve. For every conditi on in 
each set of experiments, four wells were counted to obtain the mean number of neurons 
remaining in culture. In fi gure 1 h, data are expressed as the percentage of killing and 
represent 100% – percentage of survival, from three independent experiments. 
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Animals 
Rag1−/− mice were purchased from The Jackson Laboratory and were bred under specifi c 
pathogen-free conditi ons. The 2D2 (MOG-TCR-Tg) mice were provided by Dr. V.K. Kuchroo 
(Harvard Medical School). Animal experiments and breeding were approved by the Swiss 
Veterinary Oﬃ  ce (69-200370-2003).
Adoptive transfer of TH1 and TH17 cells. 
2D2 mice were immunized subcutaneously with 200 μg of MOG35–55 
(MEVGWYRSPFSRVVHLYRNGK, obtained from GenScript) emulsifi ed in complete Freund 
adjuvant (Difco). Seven days later, mice were sacrifi ced using CO2. Spleens, axillary and 
inguinal lymphnodes were isolated, treated with 0.5 mg/ml DNase and 1 mg/ml Liberase 
(Roche) for 30 min at 37 °C and homogenized. The cells were cultured for 4 d in RPMI 1640 
supplemented with 10% fetal calf serum, 50 U/ml penicillin and 50 ug/ml streptomycin 
(Gibco) in the presence of 15 μg/ml of MOG35–55 pepti de, 10 μg/ml PolyI:C (Fluka) and 
either 2.5 ng/ml of recombinant IL-12 (PeproTech) for the promoti on of TH1 cells or 10 ng/
ml of recombinant IL-23 (PeproTech) for the promoti on of TH17 cells. Cells were harvested, 
washed and injected into recipient mice (10 × 106 cells/mouse). Animals received 200 ng 
pertussis toxin (Sigma) intraperitoneally at the ti me of transfer and 48 h later.
Flow cytometry. 
Mice were sacrifi ced 7 or 9 d aft er adopti ve transfer using CO2 and spinal cords and brains 
were isolated, treated with 0.5 mg/ml DNase and 1mg/ml Liberase for 30 min at 37 °C, 
homogenized and strained through a nylon fi lter with a pore size of 100 μm (Fisher). Aft er 
centrifugati on, cells were resuspended in 30% Percoll (Pharmacia) and were centrifuged 
at 18,500 g for 30 min at 4 °C. Viable immune cells were collected and washed extensively 
before being stained. For fl ow cytometry, anti bodies (all purchased from BD Pharmingen) 
were incubated with cells for 20 min at 4 °C and then cells were analyzed with a FACSCanto 
(BD Pharmingen) and FACSDiva soft ware. Postacquisiti on analysis was performed with 
FACSDiva Soft ware (BD Pharmingen).
Western blots for tight junction proteins
For western blots for ZO-1, occludin, JAM-1 and acti n, we lysed BBB-ECs in NP-40 buﬀ er 
(10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2 and 0.5% NP-40) supplemented with protease 
inhibitors. Fift y μg of total protein were electrophoresed on a 10% SDS-polyacrylamide 
gel under reducing conditi ons. Proteins were transferred to a polyvinylidene fl uoride 
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membrane (Biorad) and blocked for 1 h at room temperature in 5% milk. We incubated the 
membranes overnight with rabbit anti body specifi c to human occludin, rabbit anti body 
specifi c to human ZO-1 (1/250, Zymed), mouse anti body specifi c to human JAM-1 
(1/500, BD Bioscience) or mouse anti body specifi c to human acti n (1/1,000, 1 h at room 
temperature, MP Biomedicals) followed by an incubati on with horseradish peroxidase 
(HRP)-conjugated goat anti body specifi c to rabbit immunoglobulins or rabbit anti body 
specifi c to mouse immunoglobulins (1/1,000, 1 h at room temperature, DakoCytomati on). 
Specifi c binding was visualized using the ECL system (Amersham Biosciences).
Immunohistofluorescence staining for ZO-1
Cerebellum ti ssue samples from MOG-immunized C57BL/6 mice at the peak phase of 
EAE were frozen in O.C.T. and cut into 10 μm secti ons. Secti ons were permeabilized and 
blocked as described above and immunostained overnight at 4 °C with ZO-1-specifi c 
anti body (1/50, Zymed). ZO-1 signal was amplifi ed with bioti n-conjugated goat anti body 
specifi c to rabbit immunoglobulins (1/300) followed by streptavidin-Cy3 (1/300) anti body. 
Nuclei were visualized with TO-PRO3 (1/300). ZO-1 staining in highly infi ltrated vessels 
was compared to the signal in normal-appearing white matt er of the same animals.
ELISA
BBB-ECs were treated with recombinant human IL-17 (100 ng/ml), recombinant human 
IL-22 (100 ng/ml) or both. We collected supernatants at 24, 48 and 72 h and assessed 
for secreti on of CCL2 (or MCP-1) by ELISA, using a commercially available kit from BD 
Biosciences. ELISAs were carried out following the manufacturer’s instructi ons. Standards 
and samples were run in duplicate.
Statistical analysis
Migrati on data are expressed as the mean ± s.e.m. For cytokine level comparisons and 
migrati on assays, one-way analysis of variance (ANOVA) was performed followed by 
Bonferroni multi ple comparison post-test. Comparison of IL-17 and IL-22 treatments in 
permeability studies was done using two-way ANOVA, followed by the Bonferroni post-
test. Diﬀ erences between groups were considered signifi cant when P < 0.05.
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Discussion
TH17 cells in autoimmunity (current view)
While TH1 cells were long suspected to be the major pathogenic populati on in autoimmune 
diseases such as EAE, the discovery that IL-23 and not the TH1 inducing cytokines IL-12 and 
IL-18 is vital for EAE development initi ated a major paradigm shift  with regards to the role 
of TH1 cells in infl ammati on (78,79,99,154). Langrish et al. could show that IL-23 induces 
the secreti on of IL-17A by eﬀ ector T cells (101) and IL-17 expression by T cells correlates 
closely with an autoimmune pathogenic phenotype and this polarizati on patt ern was 
termed TH17 (14,15,188). While studying IL-23 under various infl ammatory conditi ons 
initi ally led to the discovery of TH17 cells, it was later found that the cytokines TGF-β 
plus IL-6 induce diﬀ erenti ati on of TH17 cells, IL-21 amplifi es the frequency of TH17 cells 
and IL-23 stabilizes the phenotype of previously diﬀ erenti ated TH17 cells (155). However, 
the exact role and functi on of these cytokines – and IL-23 in parti cular – in inducing and 
maintaining this phenotype remains a subject of debate (130).
The importance of the TH17 subset in autoimmune diseases was fi rst demonstrated in 
mice defi cient in IL-23. These mice had similar numbers of IFN-γ-producing T cells as wt 
mice but showed a dramati c decrease in IL-17-producing T cells and were resistant to the 
development of EAE and CIA (99,169).
TH17 cells are now closely associated with a number of infl ammatory autoimmune diseases 
such as RA, MS and psoriasis and are widely recognized as the pathogenic populati on in 
autoimmunity.
However, in spite of this close correlati on (99,101,169), several questi ons regarding 
the biological relevance of TH17 cytokines and their functi on, especially in autoimmune 
diseases, remain to be answered. 
TH17 cytokines in autoimmunity 
IL-17A in EAE
Transgenic targeti ng of IL-17A to T cells does not alter the pathogenesis and clinical 
development of MOG-induced EAE.
To investi gate the impact of IL-17A expressed by CNS invading T cells on the pathogenesis 
of EAE, we generated a mouse conditi onally overexpressing IL-17A in T cells. Its CD4+ T 
cells produced highly elevated levels of IL-17A but this did not result in an overt phenotype 
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neither in the macroscopic consti tuti on of the mice nor in the cellular compositi ons of 
thymus, spleen and lymph nodes. When we induced EAE in these mice, we found that IL-
17A overexpression in T cells had no eﬀ ect on the on the development of disease or cell 
infi ltrati on into the CNS and no signifi cant alterati ons were observed with respect to IFN-γ 
expressing cells. However, despite the indisti nguishable clinical scores, CNS samples from 
mice overexpressing IL-17A did show a clear and highly signifi cant increase in IL-17A+ T cells 
compared to CNS samples from mice in which the IL-17A overexpression was not induced. 
Therefore, an increase in T cell derived IL-17A in the infl amed CNS during MOG-induced 
EAE does not result in an appreciable alterati on of the disease course. Considering various 
reports describing the upregulati on of IL-17A expression in CNS lesions of MS pati ents 
(102,129), this result was surprising but cannot yet rule out IL-17A as a crucial cytokine in 
CNS infl ammati on as it could be that low IL-17A concentrati ons are suﬃ  cient to exert its 
functi on. Therefore, the IL-17A levels present under non overexpressing conditi ons might 
suﬃ  ce and the IL-17A response might be elicited once a threshold is reached. Investi gati ng 
the situati on under IL-17A defi cient conditi ons could clarify this issue.  
IL-17A functi on is redundant in the development of EAE
To improve the understanding of the role of the TH17 eﬀ ector type in autoimmunity we 
next analyzed the impact of loss of IL-17A on the development of EAE. Despite the close 
associati on of IL-17A with autoimmune infl ammati on of the CNS, the loss of IL-17A only 
marginally impeded the inducti on of the disease, which is similar to the observati ons 
made by Iwakura and colleagues (130). The functi on of IL-17A also seems to be redundant 
in other models of autoimmunity such as experimental autoimmune uveoreti niti s (EAU) 
(163). Even though IL-17A defi cient mice are suscepti ble to EAE, they do show a delayed 
onset and reduced severity and IL-17A defi cient mice or mice treated with an IL-17R 
antagonist have been reported to be resistant to the development of other autoimmune 
diseases like adjuvant-induced arthriti s (125,128). A functi on of IL-17A in autoimmunity 
can therefore not be dismissed altogether and might depend on the specifi c disease 
model and target ti ssue. In support of this assumpti on, we observed early signs of skin 
infl ammati on and ulti mately a developmental retardati on clearly visible from P4-6 on in 
mice ectopically overexpressing IL-17A. This fi nding matches the reported role of IL-17A 
in infl ammatory skin diseases like psoriasis (102). 
The non-essenti al role of IL-17A in EAE development, however, could also result from an 
involvement of other TH17 associated factors. To investi gate the exact nature of the TH17 
response in the immunized IL-17A defi cient mice, we analyzed their cytokine profi le upon 
in vitro resti mulati on with MOG pepti de under TH17 polarizing conditi ons and found IL-17F 
to be consistently and drasti cally upregulated in the lymphocytes of IL-17A defi cient mice. 
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This specifi c increase of one TH17 cytokine together with the high degree of homology 
between IL-17A and IL-17F and the shared receptor subunits, lets it seems feasible that 
these two cytokines exert similar functi ons and suggests the possibility of a compensatory 
role of IL-17F in disease development.
IL-17F in EAE
IL-17F is expressed by TH17 cells and is abundant in the infl amed CNS 
A screen performed by quanti tati ve RT-PCR of cerebellum of diseased mice revealed that 
IL-17F, like IL-17A, is highly expressed in the infl amed CNS as compared to cerebellum of 
healthy controls. To identi fy the source of IL-17F in the context of EAE we resti mulated 
in vivo primed splenocytes in vitro with MOG pepti de under TH17 polarizing conditi ons 
and found that IL-17F expression is restricted to MOG-responsive and potenti ally 
encephalitogenic CD4+ TH17 cells.
The fi nding that both cytokines are present in the infl amed CNS and mark the highly 
pathogenic TH17 populati on that has been associated with autoreacti ve lesions suggests 
that IL-17F is an encephalitogenic cytokine with functi onal relevance in CNS autoimmune 
infl ammati on.
Generati on and analysis of the IL-17F defi cient mice
To ulti mately determine whether IL-17F contributes to the development of EAE, we 
generated IL-17F defi cient mice. Against our expectati ons, the lack of IL-17F did not have 
any impact on the clinical EAE development with regards to the day of disease onset, 
maximum score or incidence. Detailed analysis of CNS-infi ltrati ng cells revealed no change 
in cell numbers or compositi on of CNS invading leukocytes.
The full suscepti bility of IL-17F-/- mice to EAE could have resulted from a compensatory 
increase in the producti on of IL-17A. However, IL-17F-/- lymphocytes showed a decrease 
in the producti on and frequency of IL-17A secreti ng cells, letti  ng a compensatory eﬀ ect 
by IL-17A seem unlikely. To defi niti vely rule out a reciprocal compensati on of IL-17A and 
IL-17F one had to investi gate mice lacking both genes. Unfortunately, the close proximity 
of the loci of these two cytokines makes it very unlikely to obtain double-defi cient mice 
by interbreeding (ca. 44 Kb in between the two genes) and therefore an approach using 
neutralizing anti bodies against one of the cytokines in the reciprocal knockout mouse 
could clarify this issue.
The decreased IL-17A secreti on in IL-17F targeted T cells was also observed in a diﬀ erent 
IL-17F defi cient mouse strain, generated by inserti on of a transcripti onal stop into exon 2 
(167). A possible explanati on is that either the gene-targeti ng of IL-17F interferes with the 
promoter/enhancer acti vity of IL-17A or that IL-17F exerts some kind of regulatory eﬀ ect 
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on IL-17A producti on. In any case, the fact that IL-17F-/- mice show drasti cally reduced 
in IL-17A levels strongly supports the assumpti on that neither IL-17A nor IL-17F, either 
individually or in combinati on, are essenti al for the development of autoimmune CNS 
infl ammati on.
IL-22 in EAE
IL-23 induces IL-22 gene expression in TH17 cells
To identi fy gene transcripts driven by IL-23, we devised two reciprocal approaches for whole 
genome transcriptomics. We compared gene-expression induced by IL-23 sti mulati on with 
those absent in Ag-driven IL-23 defi cient lymphocytes. In the fi rst approach, genes more 
than fourfold upregulated by IL-23 were identi fi ed by sti mulati ng splenocytes obtained 
from an unmanipulated mouse with recombinant IL-23 or IL-12 as a control. In the second 
approach, we immunized wt, IL-12p35-/- and IL-12/23p40-/- mice with KLH and harvested 
lymphocytes and re-challenged them in vitro prior to harvesti ng the mRNA for microchip 
analysis. We used IL-12 as a control fi rstly, because IL-12-induced gene expression is well 
characterized and secondly to eliminate IL-12-induced target genes from our analysis. To 
verify that the sti mulati on worked properly, we fi rst analyzed the expression profi le of 
genes known to be induced by IL-12 or IL-23, respecti vely. For IL-12 sti mulated cells we 
analyzed cells for IFN-γ expression, for IL-23 sti mulati on we measured IL-17 expression, 
as IFN-γ (189) and IL-17 (97) are known to be induced by IL-12 or IL-23, respecti vely. By 
combining both data sets, we found IL-22 to be specifi cally and strongly induced by IL-23. 
We could verify that other than IL-23, none of an array of diﬀ erent sti muli used elicited 
signifi cant levels of IL-22 expression in splenocytes. Previously, Dumouti er et al. could 
detect IL-22 gene expression aft er sti mulati on with IL-9 (131) – but for these experiments a 
lymphoma cell line was used and the diﬀ erent fi nding could therefore be explained by the 
oft en altered gene expression profi le of cancer cells. Also, they observed IL-22 expression 
in splenocytes upon ConA acti vati on, which was not inhibited aft er IL-9 neutralizati on 
already suggesti ng that other cytokines mediate IL-22 inducti on. Furthermore, IL-6 has 
been shown to be suﬃ  cient for the inducti on of IL-22 from naïve CD4+ T cells by another 
group (140). For these experiments, FACS sorted naïve CD4+ cells have been used and 
additi onally sti mulated with anti -CD3 and anti -CD28 anti bodies which supply an unspecifi c 
and very strong sti mulus to T cells. Therefore, one cannot directly compare this fi nding to 
ours. In our model, IL-23 was clearly the only sti mulus able to induce IL-22 producti on in 
vitro. This observati on is further supported by other in vivo data: Although both IL-6 and 
IL-23 sti mulate IL-22 producti on in vitro (140), only IL-23 seems to be indispensable in vivo 
for IL-22 inducti on under several infecti ous or autoimmune-disease conditi ons (141,142). 
Also, IL-6 is not essenti al for IL-22 inducti on in ConA-induced hepati ti s and C. rodenti um 
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infecti on models (141,150). 
When we sti mulated purifi ed CD4+ as well as CD8+ T cells obtained from OT-II and OT-I 
mice, respecti vely, with cognate pepti de pulsed DCs we found that only TcR Tg CD4+ T cells 
made IL-22, verifying the noti on that TH cells and not CTLs are the main source of IL-22. It 
was, however, recently reported that IL-23 induces IL-22 producti on also from CD8+ T cells 
and γ/δ T cells, as well as monocytes and CD11c+ DCs (140,141). This is not in line with our 
fi nding and also contradicts a previous report showing that monocytes do not express IL-
22 aft er LPS sti mulati on in which case IL-23 should also be present (137). However, CD8+ 
T cells as well as monocytes and DCs do express the IL-23R (91,92) and could therefore 
potenti ally respond to its engagement with IL-22 producti on but it needs to be further 
elucidated weather they do so only under certain conditi ons or weather other reasons 
are responsible for the diﬀ ering results regarding the IL-22 producing cell type. 
In agreement with Liang et al., we found IL-22 to be highly expressed by the TH17 cell 
subtype (139), which is closely associated with eﬀ ector functi ons in autoimmunity (170) 
suggesti ng that IL-22 could potenti ally serve a pathogenic functi on during EAE. 
IL-22 is expressed by CNS invading encephalitogenic TH cells
We determined the inducti on of IL-22 expression in a more physiologic manner in response 
to cognate Ag presented by DCs. MOG-reacti ve T cells clearly expressed high levels of 
IL-22 and also IL-17A aft er encounter with their cognate anti gen. This response was 
dependent on IL-23 as reduced levels of IL-22 and IL-17 were detectable when T cells were 
co-cultured with DCs obtained from p40IL-12/23-/- mice. Our fi ndings together with data 
from a similar experiment reported by Liang et al. in which recombinant IL-23 was added 
during a recall assay further underline the importance of IL-23 for IL-22 inducti on (139). 
We analyzed the expression of IL-22 in mice with autoimmune infl ammati on and detected 
a signifi cant producti on of IL-22 by encephalitogenic, CNS-infi ltrati ng lymphocytes aft er 
re-encounter with their cognate MOG-anti gen. Similar to IFN-γ and IL-17, IL-22 expression 
by CNS-infi ltrati ng lymphocytes increased with disease severity. 
To this end, all data hint towards IL-22 expression actually marking a highly pathogenic 
and proinfl ammatory populati on of autoaggressive T cells as recently claimed by Bett elli 
et al. (170), implicati ng IL-22 to exert a pathogenic functi on during EAE.
IL-22 defi cient mice are fully suscepti ble to EAE
In order to determine whether IL-22 actually contributes to the development of EAE or 
whether the crisp correlati on between IL-22 expression and encephalitogenicity is only an 
epiphenomenon, we generated IL-22-/- mice by gene-targeti ng. The genomes of the C57/
Bl6 mouse strain possess two IL-22 genes, IL-22 α and β. The IL-22 β gene contains several 
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single nucleoti de changes and a deleti on covering the fi rst noncoding exon and a segment 
of a putati ve promoter, already suggesti ng that the IL-22β gene may not be expressed. We 
verifi ed the absence of IL-22 by genomic PCR, RT-PCR using primers amplifying both IL-22 
α and β and ELISA in the IL-22-/- mouse, proofi ng that the knockout of the IL-22α gene was 
successful and that the IL-22β gene is indeed not expressed in the C57/B6 mouse strain.
IL-22 has been reported to have a role in proliferati on of some cell types such as 
kerati nocytes or breast cancer cells (145,190). IL-22-/- lymphocytes, however, behaved 
similar to wt cells aft er re-encounter of cognate Ag with regards to proliferati ng capacity as 
well as cytokine expression profi le. Therefore, IL-22 defi ciency does not impair lymphocyte 
functi on in general, which was expected due to the missing IL-22R expression on these 
cells (191,192).
When we induced EAE in the IL-22-/- mice, we discovered to our surprise that IL-22-/- mice 
develop EAE with the same severity, day of onset and clinical manifestati ons as wt mice. 
This fi nding clearly dismisses IL-22 as a major pathogenic player in the development of 
autoimmune CNS infl ammati on. 
IL-22 in other disease models
The functi on of IL-22 in autoimmunity however cannot be dismissed altogether. Wolk et 
al. reported that elevated levels of IL-22 can be found in the blood of psoriati c pati ents 
and ear-skin acanthosis and infl ammati on induced by the applicati on of IL-23 is slightly 
decreased when IL-22 is absent (140,145). Furthermore, an upregulati on of IL-22 has 
been described in CD and UC, as well as in preclinical mouse IBD models or RA pati ents 
(135,148,193). In additi on to its proinfl ammatory role, protecti ve functi ons of IL-22 have 
also been described (123,149,150). In support of a potenti ally protecti ve functi on of IL-
22, we observed that IL-22-/- mice developed more severe disease in a model of allergic 
asthma with increased eosinophil invasion into the lung. The IL-22R is not expressed on 
eosinophils, but on epithelial cells of the respiratory tract. Therefore, it is likely that IL-
22 exerts an indirect functi on on eosinophil recruitment through mediators secreted by 
epithelial cells in response to IL-22R engagement. Further proving a protecti ve role of IL-22 
in airway infl ammati on, administrati on of recombinant IL-22 att enuates the infl ammatory 
response in the lung (Taube C., Kreymborg K., manuscript in preparati on). Interesti ngly, IL-
17F has been reported to be present in the airways of pati ents with allergic asthma and a 
mutati on in the IL-17F gene was shown to be associated with human asthma and chronic 
obstructi ve pulmonary disease (158,194) which suggests that there might also be a role of 
IL-17F in asthma. Therefore, we will in the future also investi gate the role of IL-17F in this 
disease by uti lizing the IL-17F-/- mice in our model of allergic asthma.
In conclusion, IL-22 does not contribute to autoimmune infl ammati on of the CNS and 
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cannot be categorized as a cytokine with either clearly pathogenic and protecti ve 
properti es but its functi on seems to depend on the specifi c situati ons and target cells.
IL-22 and IL-17 mediated permeabilization of the BBB
We could detect IL-17R and IL-22R on the surface of a subset of human BBB epithelial cells 
in primary culture. In situ, however, IL-17R and IL-22R were undetectable in CNS material 
from subjects without MS but strongly expressed on CNS vessels within heavily infi ltrated 
MS lesions. We could further show that IL-17 and IL-22 could aﬀ ect BBB permeability 
since additi on of these cytokines to monolayers of human BBB epithelial cells induced 
a marked and sustained increase in the diﬀ usion of fl uorescence-labeled BSA and for IL-
17 it coincided with a decrease in the expression of occludin and ZO-1, two important 
ti ght juncti on–associated molecules. These results are in line with recent data showing a 
disrupti on of ti ght-juncti on proteins in highly infi ltrated vessels of MS lesions (185). We also 
explored the capacity of IL-17 and IL-22 to modulate lymphocyte migrati on across human 
BBB epithelial cells and found that IL-17 and IL-22 promote transmigrati on of human ex 
vivo CD4+ T cells, most likely through enhanced BBB epithelial cell mediated secreti on of 
CCL2 (or MCP-1). Considering the recently reported ability of IL-17A to very eﬃ  ciently 
induce chemokine producti on by lung epithelial cells it could very well be that IL-17 and 
IL-22 exert a similar eﬀ ect on BBB epithelial cells (119). These results strongly suggest that 
TH17 cells, through the acti on of IL-17 and IL-22, play a unique role in permeabilizing the 
human BBB both to soluble molecules and to circulati ng CD4+ T cells. 
However, given the IL-17R and IL-22R are only expressed in the infl amed CNS and not 
under healthy conditi ons, IL-17 and IL-22 are unlikely to be responsible for the initi al BBB 
breakdown. More likely, these cytokines contribute to further BBB permeabilizati on in 
an already infl amed environment – sti ll not explaining the fundamental and crucial steps 
leading to CNS infl ammati on.
Furthermore, when we generated MOG-specifi c TH1 and TH17 lymphocytes from 2D2 mice 
in vitro and transferred these separately into Rag1-/- mice we found equal numbers of TH 
cells in the CNS 7 d aft er transfer, regardless of whether donor cells were polarized into 
TH1 or TH17 cells. These data indicate, that high expression of IL-17 and IL-22 – as it is the 
case for TH17 but not TH1 cells – cannot be the only prerequisite to invade the CNS and 
further points toward the existence of additi onal factors essenti al in the process of CNS 
infl ammati on.
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TH17 function beyond IL-17A, IL-17F and IL-22
Evaluati ng all data generated by deleti on of the TH17 eﬀ ector cytokines IL-17A, IL-17F and 
IL-22 or the induced overexpression of IL-17A it is clear that none of those TH17 cytokines 
are key players in autoimmune disease like EAE. 
Given the strong phenotype of IL-23 defi cient mice in autoimmunity, it is likely that there 
are additi onal factors induced by IL-23 or thus far unidenti fi ed TH17 cytokines or factors 
with crucial functi ons in autoimmune infl ammati on. This concept is also supported by 
the report of McGeachy et al., who observed that IL-23 driven TH cells, but not TGF-β/IL-6 
driven TH cells were encephalitogenic, regardless of their secreti on of IL-17A (115).
Cytolyti c enzymes
Employing an in vitro model of the human BBB using human brain-derived microvascular 
endothelial cells we found that human TH17 lymphocytes migrated avidly across the BBB. 
We could detect numerous CD45RO+ cells immunopositi ve for IL-17 or IL-22 in highly 
infi ltrated MS lesions, but not in normal-appearing white matt er or non-infl amed brain 
specimens. We observed that, whereas virtually no ex vivo CD4+CD45RO+ cells produced 
cytolyti c enzymes, granzyme B was expressed by IL-17– or IL-22–producing CD4+CD45RO+ 
cells aft er 6 d of culture with IL-23. Strikingly, the cells coexpressing IL-17 and IL-22 were 
the major populati on expressing granzyme B.  Granzyme B+ TH17 cells had the capacity to 
kill human fetal neuron–enriched cultures and showed considerable cytolyti c acti vity as 
compared to unacti vated T cells. 
CD4+ cells are typically known for their capacity to provide helper functi ons during an 
immune response and cytolyti c acti vity was long thought to be limited to CD8+ T cells. 
However, over the past two decades the ability of CD4+ T cells to display cytotoxic potenti al 
has been reported in both mouse and human, although the existence and signifi cance 
of CD4+ CTLs have been disputed or disregarded (195). It has been suggested earlier, 
that CD4+ CTLs use the perforin-dependent cytotoxic mechanism, rather than the Fas-
dependent pathway and recent reports fi nally proofed that CD4+ T cells are also able to 
perform perforin and granzyme-mediated killing and the in vivo existence and relevance 
of cytotoxic CD4+ T cells has been established (20). Our observati on regarding granzyme 
B expression by CD4+ T cells further refi nes the phenotype of human TH17 lymphocytes 
as cells coexpressing not only IL-17 and IL-22 but also additi onal mediators contributi ng 
to their encephalitogenic potenti al, among them cytolyti c enzymes like granzyme B. 
Therefore, the acti on of TH17 cells clearly extends beyond the proinfl ammatory infl uence 
of IL-17A, IL-17F and IL-22. 
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GM-CSF
In the whole genome transcriptomics approach we performed to reveal IL-23 induced 
gene transcripts, we identi fi ed IL-22 to be highly inducible by IL-23 but also further genes 
which expression was, albeit to a lesser degree, IL-23 dependent. Tnfrsf11b, Pkia and 
Pgcp-pending were upregulated upon IL-23 sti mulati on and Csf2, Dab2, Klra16, Hdgf and 
IL-1α were downregulated in the absence of IL-23. The IL-23 dependent gene expression 
was verifi ed by real ti me PCR and of these potenti al candidate genes, we found only 
colony-sti mulati ng factor 2 (Csf2) expression to be clearly upregulated upon sti mulati on 
with IL-23 as well as reduced in p40-/- lymphocytes. There was no signifi cant diﬀ erence in 
the expression of all the other genes we tested. 
Colony-sti mulati ng factor 2, bett er known as granulocyte macrophage colony-sti mulati ng 
factor (GM-CSF), is the major regulator involved in the control of granulocyte and 
macrophage linage populati ons at all stages of maturati on. Interesti ngly, GM-CSF plays 
a central role in maintaining chronic infl ammati on and its role in autoimmune-mediated 
demyelinati on has only recently been described. GM-CSF-/- mice are resistant to EAE, 
display decreased anti gen-specifi c proliferati on of splenocytes and fail to sustain immune 
cell infi ltrates in the CNS, thus revealing key acti viti es for GM-CSF in the development 
of infl ammatory demyelinati ng lesions and control of migrati on and/or proliferati on of 
leukocytes within the CNS (196). Furthermore, T cells expressing GM-CSF induce severe 
and chronic EAE (197). Ifergan et al. recently demonstrated that through secreti on of 
TGF-β and GM-CSF, human BBB endothelial cells promote the diﬀ erenti ati on of a 
subset of peripheral blood CD14+ monocytes into CD83+ (myeloid) DCs which express 
CD209 and secrete IL-12p70, TGF-β and IL-6, favoring the diﬀ erenti ati on of disti nct 
CD4+ T cell populati ons into IFN-γ- or IL-17- secreti ng cells (198). Based on these data 
one could speculate a possible mechanism for the acti on of GM-CSF in mediati ng CNS 
infl ammati on being the recruitment of peripheral blood derived monocytes, as well as 
their diﬀ erenti ati on into functi onal DCs, which have been proven to be essenti al in EAE 
pathogenesis (36). Taken together, GM-CSF might be an additi onal candidate for a thus 
far unidenti fi ed IL-23 dependent “encephalitogenicity-gene” potenti ally explaining the 
strong phenotype observed in IL-23-/- mice.
TH17 cells in autoimmunity (reconsidered)
The discovery of the TH17 lineage and the biological functi ons of its eﬀ ector cytokines 
undoubtedly advanced our understanding of CD4+ T cells in adapti ve immunity. But 
despite the recent progress many issues parti cularly concerning their pathogenic role in 
autoimmunity remain inconclusive. 
First of all, data obtained from experiments using in vitro diﬀ erenti ated TH17 cells have to 
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be evaluated with great care since the protocols widely used for this purpose are highly 
arti fi cial. They include the administrati on of unphysiologically high doses of a cohort of 
cytokines, factors and neutralizing anti bodies that are under no circumstances present like 
this in vivo. Therefore, while these in vitro experiments help to gain insights into conditi ons 
ideal to polarize T cells toward a desired phenotype, they can only give a vague idea as to 
how these cells functi on in vivo. Furthermore, the conditi ons promoti ng human TH17 cell 
diﬀ erenti ati on are not universally established and how IL-6, TGF-β, IL-23 and other factors 
control TH17 cells in vivo under various infl ammatory conditi ons is sti ll unclear. In fact, T 
cells are exposed to a complex cytokine milieu in vivo and display considerable plasti city. 
For example, many of the CD4+ T cells isolated from an infl amed CNS during EAE do not 
exclusively belong to either the TH1 or TH17 T cell subsets as currently defi ned because 
they coproduce IL-17 and IFN-γ. 
Strikingly, many studies claiming TH17 cytokines to be the main driving force behind 
ti ssue infl ammati on are based on correlati ve relati onships. For example, the decreased 
expression of IL-17A and IL-17F observed in IL-23- or IL-6-defi cient mice, which are 
resistant to EAE (99,199-202), has led to an overhasty interpretati on making these 
cytokines responsible for the observed phenotype though the restrained producti on of IL-
17A and IL-17F much rather is a symptom than the cause of the EAE resistance. However, 
given the strong phenotype of IL-23 defi cient mice in autoimmunity which cannot – as we 
have demonstrated here – be explained by so far identi fi ed TH17 cytokines such as IL-17A, 
IL-17F and IL-22, it is likely that there are additi onal factors or mechanisms induced by IL-
23 or thus far unidenti fi ed TH17 cytokines driving autoimmune infl ammati on.
Finally, TH17 cells and their eﬀ ector cytokines can also have protecti ve roles during 
infl ammati on (123,149,150) and the balance of their functi ons is not well understood 
during the processes of many autoimmune and infecti ous diseases.
Taken together, the wish to identi fy the one culprit in autoimmunity (together with 
facilitated publishing when including the right code word in line with the current trend) can 
lead to a simplisti c black and white percepti on of the in fact very complex and reciprocal 
interplay of cells and factors inducing the development of autoimmune infl ammati on. 
This has lead to a biased interpretati on of the role and functi on of TH1 and TH2 cells in the 
past and now puts the blame on TH17 cells.
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